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ABSTRACT                                                                 ENGLISH            
Background. Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder with complex presentations consisting of different motor and non-motor symptoms. 
The multisystem and progressive nature of PD has made it a complicated entity with broad 
variation in manifestations and reciprocal effects on several aspects of daily life.  
Aims. This doctoral thesis investigated different neuroepidemiologic aspects of PD and 
parkinsonism including its screening and prevalence in the urban area of Tehran, Iran, 
nutritional status and risk factors for malnutrition, clinical and psychiatric features, health-
related quality of life (HRQoL) and its determinants in Iranian PD patients. For this purpose, 
we also aimed to validate several questionnaires and make a new screening instrument.   
Study I. Psychometric properties of the Persian-translated version of the short-form 
Parkinson’s disease questionnaire (PDQ-8) were assessed in 114 Iranian patients with PD 
consecutively recruited from an outpatient Movement Disorder Clinic. The Cronbach’s alpha 
coefficient of the entire PDQ-8 was 0.740 (95% CI: 0.661-0.806). Replacement of PDQ-8 
items with other questions with the highest internal consistency within each dimension of the 
long-form PDQ (PDQ-39) did not further improve reliability. The Persian version of the 
PDQ-8 was shown to be a valid and reliable instrument to assess HRQoL in Iranian PD 
population especially in mental and behavioral aspects. PDQ-8 is a practical and informative 
instrument in daily clinical practice where clinicians are in shortage of time and need a 
validated self-reported brief questionnaire.  
Study II. To develop a new instrument for screening of parkinsonism in community-based 
surveys, a comprehensive questionnaire consisting of 25 items on different PD symptoms 
was filled in 157 patients with parkinsonism and 110 controls. Using the concept of clinical 
utility index (CUI), six items on “stiffness & rigidity”, “tremor & shaking”, “troublesome 
buttoning”, “troublesome arm swing”, “feet stuck to floor” and “slower daily activity” 
demonstrated good validity (CUI≥0.64) to be included in the new screening tool . We 
introduced a new set of six items to screen parkinsonism, which showed higher diagnostic 
values [area under curve (AUC)=0.977] compared to the previously developed 
questionnaires. This new instrument could be used in population-based surveys to screen 
parkinsonism in poor-resource settings. 
Study III. Following a random multistage sampling of the households within the network of 
“Health Centers” with 374 subunits in all 22 urban districts of Tehran, 20,621 individuals 
answered the baseline checklist and the screening questionnaire developed in study II. Data 
from 19,500 persons aged ≥30 years were entered in the final analysis. A total number of 157 
cases were positively screened for parkinsonism that resulted in age- and sex-adjustment 
prevalence rates of 222.9/100,000 (95% CI: 160-300) and 285/100,000 (95% CI: 240-329) 
based on the real Tehran population and “WHO World Standard Population”, respectively. 
The male/female ratio of probable parkinsonism was 1.62 and there was a steady increase by 
advancing age. The calculated rates for the prevalence of parkinsonism in our study are closer 
to the reports from some European and Middle-East countries, higher than reports from the 
Eastern Asian and African populations, and lower than Australia. The prevalence rate of 
>200/100,000 for parkinsonism in Tehran, Iran is considered as a medium-to-high rate. 
Study IV. Nutritional status was evaluated in 143 Iranian PD patients and 145 age- and sex-
matched controls by means of the validated Persian version of the mini-nutritional assessment 
(MNA). The mean of total MNA score was not significantly different between the two groups 
[24.4 (SD=3.8) in controls vs. 25.1 (SD=3.4) in PD patients, p=0.094]. Three (2.1%) PD 
patients were suffering from malnutrition and another 37 (25.9%) were at risk of 
  
malnutrition; while in control group similar feature was observed (2.0% malnourished and 
35.2% at risk of malnutrition, p=0.228). Our findings indicated similar nutritional status 
among mild-to-moderate PD patients and matched controls from the same community. 
However, nearly one third of PD population were either malnourished or at risk of 
malnutrition necessitating more attention towards nutritional assessment in PD. 
Study V. Factors affecting nutritional status were investigated in 150 PD patients including a 
comprehensive list of motor and non-motor scales. The total score of the Unified Parkinson's 
disease rating scale (UPDRS) scale (r=-0.613, p<0.001) and PD duration (r=-0.284, p=0.002) 
had a significant inverse correlation with the total MNA score. A higher Hoehn and Yahr 
stage [2.5 vs. 2.0, p<0.001], more severe anxiety [8.8 vs. 5.9, p=0.002], depression [9.0 vs. 
3.6, p<0.001] and fatigue [5.4 vs. 4.2, p<0.001] were observed in PD patients with nutritional 
insufficiency. Except for stigma, all other domains of the HRQoL significantly correlated 
with the total MNA score. We showed that disease duration, severity of motor and psychiatric 
symptoms (depression, anxiety) and fatigue associated with nutritional status in PD, which 
itself affected different aspects of HRQoL especially the emotional well-being and mobility.  
Study VI. A broad spectrum of demographic, motor and non-motor characteristics were 
evaluated in 157 PD patients consisting of comorbidity profile, nutritional status, UPDRS 
(total items), psychiatric symptoms (depression, anxiety), fatigue and psychosocial 
functioning through physical examination, validated questionnaires and scales. Structural 
equation model (SEM) and multivariate regressions were applied to find determinants of 
Parkinson’s disease severity index (PDSI) and different domains of HRQoL (PDQ-39). 
Female sex, anxiety, depression and UPDRS-part II scores were the significant independent 
determinants of PDSI. A structural model consisting of global motor, global non-motor and 
co-morbidity indicator as three main components was able to predict 89% of the variance in 
HRQoL. However, outstanding heterogeneities in the pattern and determinants of HRQoL 
were found among different PD phenotypes.  
Conclusions. We showed a medium-to-high prevalence rate for suspicious parkinsonism in 
Iranian population living in the urban area of Tehran by means of a novel 6-item screening 
instrument. Similar nutritional status was found in mild-to-moderate PD patients and matched 
controls from the same community. Yet, approximately one third of people with mild-to-
moderate PD were either malnourished or at risk of malnutrition. Duration of PD, severity of 
motor symptoms, depression, anxiety and fatigue associated with nutritional status in PD 
patients. Motor symptoms affecting activities of daily living (ADL), depression, anxiety and 
female sex were found to be the strongest independent determinants of HRQoL in Iranian PD 
population. Clear heterogeneities were found in the pattern and determinants of HRQoL in 
different PD phenotypes, which should be considered during the assessments and developing 
personalized interventions to improve life quality in PD patients with different prominent 
features. 
Keywords. Parkinson’s disease, Parkinsonism, Neuroepidemiology, Validation, Reliability, 
Psychometric properties, Health-related quality of life, Screening instrument, Diagnostic 
value, Prevalence, Community-based, Door-to-door study, Nutritional status, Malnutrition, 
Determinant factor, Motor symptom, Non-motor symptom, Psychiatric features, Anxiety, 
Depression, Fatigue, Phenotype, Heterogeneity           
  
   
ABSTRACT                                                                SWEDISH            
Bakgrund. Parkinsons sjukdom (PS) är den näst vanliga neurodegenerativa sjukdomen med 
komplexa sjukdomsyttringar bestående av olika motoriska och icke-motoriska symtom. Den 
komplexa och progressiva karaktären av PS har medfört att det finns en bred variation av 
olika sjukdomsmanifestationer och även de effekter som de kan ha på det dagliga livet. 
Målsättning. Denna doktorsavhandling har undersökt olika neuroepidemiologiska aspekter 
av PS och parkinsonism inkluderande screening och prevalensundersökning i huvudstaden 
Teheran, Iran, nutritionsstatus och riskfaktorer för malnutrition, somatiska och psykiatriska 
symtom, hälsorelaterad livskvalitet (HRQoL) och dess determinanter hos iranska PS-
patienter. För detta ändamål validerades också flera frågeformulär och ett nytt 
screeninginstrument utvecklades.  
Studie I. Psykometriska egenskaper hos den persiska versionen av kortformen av 
frågeformuläret ”Parkinson’s Disease Questionnaire” (PDQ-8) genomfördes på 114 iranska 
patienter med PS, konsekutivt rekryterade från en neurologisk motorikenhet. Cronbach alpha 
koefficienten för hela PDQ-8 var 0.740 (95% CI: 0.661-0.806). Vid utbyte av frågor från 
PDQ-8 med andra frågor med den högsta interna konsistensen inom varje dimension av 
långversionen av frågeformuläret (PDQ-39), förbättrade inte reliabiliteten. Den persiska 
versionen av PDQ-8 visade sig vara valid och utgöra ett reliabelt instrument för att bedöma 
HRQoL i en iransk PS-population, särskilt vad det gäller mentala och beteendemässiga 
aspekter. PDQ-8 är ett praktiskt och informativt instrument för dagligt kliniskt bruk där 
läkare ofta har brist på tid och behöver ett validerat, självrapporterande, kort frågeformulär. 
Studie II. Utvecklandet av ett nytt instrument för screening av parkinsonism i 
populationsstudier togs fram genom att sammanställa 25 frågor om olika PS symtom. 
Formuläret fylldes i av 157 patienter med parkinsonism och 110 kontroller. Genom att 
använda konceptet ”Clinical Utility Index” (CUI), uppvisade 6 frågor god validitet 
(CUI≥0.64) och kunde inkluderas i det nya screeninginstrumentet. De nyintroducerade 
frågorna för att screena för parkinsonism var:  ”stelhet och rigiditet”, ”skakningar”, ”svårt att 
knäppa knappar”, “dålig armpendling”, ”fastnande med fötterna”, ”besvär med dagliga 
aktiviteter”. Formuläret visade högre diagnostiska värden (area under curve; AUC=0.977) 
jämfört med tidigare utvecklade frågeformulär. Detta nya instrument skulle därmed kunna 
användas för att screena för parkinsonism i populationsbaserade studier i resurssvaga 
områden.  
Studie III. Genom att använda en slumpmässig flerstegsmetod och rekrytera personer från 
olika hushåll inom ett nätverk kallat ”Health Centers” med 374 enheter inom alla Teherans 24 
stadsdistrikt, kunde 20,621 personer besvara en checklista och det frågeformulär som 
utvecklats i Studie II. Av dessa personer kunde data från 19,500 personer >30 år inkluderas i 
den slutliga analysen. Totalt 157 personer screenade positivt för parkinsonism, vilket 
resulterade i ålders- och könsjusterade prevalenssiffror om 222.9/100,000 och 285/100,000 
baserat på den uppgivna Teheranska populationen respektive WHO World Standard 
Population. Könsrelationen man/kvinna för sannolik parkinsonism var 1.62 och det var en 
ökning med ökande ålder. De kalkylerade siffrorna för prevalensen av parkinsonism i vår 
studie liknar de siffror i rapporter från vissa Europeiska och MellanÖstern länder men är 
högre än siffror från Östasien och Afrikanska populationer och lägre än de från Australien. 
Prevalenssiffran på >200/100,000 för parkinsonism i Teheran, Iran, får anses som en 
medel/hög siffra. 
Studie IV. Nutritionsstatus utvärderades hos 143 iranska PS-patienter och 145 ålders- och 
könsmatchade kontroller genom att använda den validerade persiska versionen av mini-
nutritional assessment (MNA). Medelvärdet av totala MNA poängen var inte signifikant 
skiljd mellan grupperna (24.4; SD=3.8 för kontroller mot 25.1; SD=3.4 hos PS patienter; 
  
p=0.094). Tre (2.1 %) PS patienter uppvisade malnutrition och ytterligare 37 (25.9%) var i 
riskzonen för malnutrition. Motsvarande  siffror i kontrollgruppen var 2.0% malnutrierade 
och 35.2% med risk för malnutrition (p=0.228). Våra fynd indikerar likartat nutritionsstatus 
hos patienter med mild /moderat  sjukdomsgrad av PS och matchade kontroller från samma 
område. Dock var nästan en tredjedel av PS populationen malnutrierad eller i riskzonen för 
malnutrition, vilket pekar på att man bör vara uppmärksam på nutritionsbedömningar vid PS. 
Studie V. Faktorer som påverkar nutritionsstatus undersöktes hos 150 PS-patienter genom en 
omfattande genomgång av motoriska och icke-motoriska skalor. Den totala poängen från 
frågeformuläret ”Unified Parkinson’s Disease Rating Scale” (UPDRS) (r=-0.613; p<0.001) 
och PS-durationen (r=-0.284; p=0.002) uppvisade en signifikant omvänd korrelation med 
totala MNA poängen. Högre stadier av Hoehn och Yahr [2.5 vs. 2.0; p<0.001], svår oro [8.8 
vs. 5.9; p=0.002], depression [9.0 vs. 3.6; p<0.001] och fatigue [5.4 vs. 4.2; p<0.001] 
observerades hos PS-patienterna med nutritionsbrist. Förutom stigma korrelerade alla andra 
domäner i HRQoL signifikant med totala MNA poängen. Vi visade att sjukdomsduration, 
svårighetsgrad av motoriska och psykiatriska symtom (oro, depression) och fatigue var 
associerade med PS patienternas nutritionsstatus, som påverkade olika aspekter av HRQoL 
och särskilt emotionellt välbefinnande och rörlighet. 
Studie VI. Ett brett spektrum av demografiska, motoriska och icke-motoriska variabler 
utvärderades genom fysisk undersökning och validerade frågeformulär hos 157 PS patienter. 
Dessa bestod av komorbiditet,, nutritionsstatus, UPDRS, psykiatriska symtom(depression, 
oro), fatigue och psykosocial funktion. Statistiska metoder med ”Structural equation model” 
(SEM) och multivariat regression användes för att hitta determinanter till ”Parkinson´s 
disease severity index” (PDSI) och olika domäner av HRQoL (PDQ-39). Kvinnligt kön, oro, 
depression och UPDRS del II var signifikant oberoende determinanter för PDSI. En 
strukturerad modell bestående av globalt motoriska, globalt icke-motoriska och komorbiditets 
indikatorer som de tre huvudkomponenterna kunde predicera 89 % av variansen i HRQoL. 
Dock var olika heterogeniteter i mönstret och determinanterna för HRQoL olika för olika 
fenotyper av PD. 
Konklusion. Vi har påvisat en medel/hög prevalens för suspekt parkinsonism i en Iransk 
population som bor i Teherean genom att använda ett nyutvecklat 6-frågors screening 
formulär. Samma nutritionsstatus förelåg hos mild/moderat svårighetsgrad av PS och 
matchade kontroller från samma område. Ändock var en tredjedel av personerna med 
mild/moderat PS antingen malnutrierade eller i riskzonen för malnutrition. PS durationen, 
svårighetsgraden av motoriska symtomen, depression, oro och fatigue var associerade med 
nutritionsstatus vid PS. Motoriska symtom som påverkar dagliga aktiviteter (ADL), 
depression, oro och kvinnligt kön var de starkaste oberoende determinanterna för HRQoL i 
en Iransk PS population. Olika heterogeniteter fanns i mönstret och determinanterna för 
HRQoL hos olika fenotyper av PS. Detta bör uppmärksammas vid bedömningar och vid 
användandet av individualiserade interventione för att förbättra livskvaliteten hos PS patienter 
med olika fenotyper. 
  
  
   
            NAISREP                                                                 TCARTSBA
ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺩﻭﻣﻴﻦ ﺍﺧﺘﻼﻝ ﻧﻮﺭﻭﺩژﻧﺮﺍﺗﻴﻮ ﺷﺎﻳﻊ ﺍﺳﺖ ﻛﻪ ﺗﻈﺎﻫﺮﺍﺗﻲ ﺑﺴﻴﺎﺭ ﻣﺘﻨﻮﻉ ﺷﺎﻣﻞ ﻋﻼﻳﻢ ﻣﺨﺘﻠﻒ ﺣﺮﻛﺘﻲ  :ﺯﻣﻴﻨﻪﭘﻴﺶ
ﺭﺍ ﺑﻪ ﻳﻚ ﺑﻴﻤﺎﺭﻱ ﭘﻴﭽﻴﺪﻩ ﺑﺎ ﻧﺎﻫﻤﺨﻮﺍﻧﻲ ﺑﺴﻴﺎﺭ ﺩﺭ ﺗﻈﺎﻫﺮﺍﺕ ﻨﺪﺳﻴﺴﺘﻤﻲ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ، ﺁﻥﻃﺒﻴﻌﺖ ﭘﻴﺸﺮﻭﻧﺪﻩ ﻭ ﭼ. ﻭ ﻏﻴﺮﺣﺮﻛﺘﻲ ﺩﺍﺭﺩ
 .   ﻱ ﺑﻴﻤﺎﺭﺍﻥ ﺩﺍﺷﺘﻪ ﺑﺎﺷﺪﻫﺎﻱ ﮔﻮﻧﺎﮔﻮﻥ ﺯﻧﺪﮔﻲ ﺭﻭﺯﻣﺮﻩﺗﻮﺍﻧﺪ ﺍﺛﺮﺍﺕ ﻣﺘﻘﺎﺑﻠﻲ ﺑﺮ ﺟﻨﺒﻪﺑﻴﻦ ﺑﻴﻤﺎﺭﺍﻥ ﻣﺨﺘﻠﻒ ﺑﺪﻝ ﻛﺮﺩﻩ ﻛﻪ ﻣﻲ
ﻱ ﺷﻬﺮﻱ ﺗﻬﺮﺍﻥ ﺩﺭ ﻥ ﻭ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺩﺭ ﺣﻮﺯﻩﻫﺎﻱ ﮔﻮﻧﺎﮔﻮﻥ ﻧﻮﺭﻭﺍﭘﻴﺪﻣﻴﻮﻟﻮژﻳﻚ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﺩﺭ ﺍﻳﻦ ﭘﺮﻭژﻩ ﺟﻨﺒﻪ: ﺍﻫﺪﺍﻑ
ﺍﻱ، ﺗﻈﺎﻫﺮﺍﺕ ﺑﺎﻟﻴﻨﻲ ﻭ ﺭﻭﺍﻧﺸﻨﺎﺧﺘﻲ، ﻏﺮﺑﺎﻟﮕﺮﻱ ﻭ ﺷﻴﻮﻉ، ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ: ﻛﺸﻮﺭ ﺍﻳﺮﺍﻥ ﻣﻮﺭﺩ ﺑﺮﺭﺳﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺘﻪ ﺍﺳﺖ ﻛﻪ ﻋﺒﺎﺭﺗﻨﺪ ﺍﺯ
ﻫﺎﻱ ﭘﺮﺳﺸﻨﺎﻣﻪ، ﺍﻋﺘﺒﺎﺭ ﻫﻤﭽﻨﻴﻦ. ﻫﺎﻱ ﺁﻥ ﺩﺭ ﺑﻴﻤﺎﺭﺍﻥ ﺍﻳﺮﺍﻧﻲ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥﻛﻨﻨﺪﻩﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﻭ ﺗﻌﻴﻴﻦ
  .    ﻫﺎﻳﻲ ﺟﺪﺍﮔﺎﻧﻪ ﻣﻮﺭﺩ ﺍﺭﺯﻳﺎﺑﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺘﻪ ﻭ ﺍﺑﺰﺍﺭ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺟﺪﻳﺪﻱ ﻧﻴﺰ ﺳﺎﺧﺘﻪ ﺷﺪﻣﺘﻌﺪﺩ ﻣﻮﺭﺩ ﺍﺳﺘﻔﺎﺩﻩ ﺩﺭ ﺍﻳﻦ ﭘﺮﻭژﻩ ﺩﺭ ﭘﮋﻭﻫﺶ
 esaesid s’nosnikraPﻱ ﻱ ﭘﺮﺳﺸﻨﺎﻣﻪﻱ ﻓﺎﺭﺳﻲ ﻭ ﻛﻮﺗﺎﻩ ﺷﺪﻩﻫﺎﻱ ﺳﺎﻳﻜﻮﻣﺘﺮﻳﻚ ﻧﺴﺨﻪﻭﻳﮋﮔﻲ: 1ﭘﮋﻭﻫﺶ 
ﮔﻴﺮﻱ ﻏﻴﺮ ﺍﺣﺘﻤﺎﻟﻲ ﺭﻭﺵ ﻧﻤﻮﻧﻪﻃﻮﺭ ﻣﺘﻨﺎﻭﺏ ﻭ ﺑﻪﺍﻳﺮﺍﻧﻲ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻛﻪ ﺑﻪﺑﻴﻤﺎﺭ  411ﺩﺭ  )8-QDP( eriannoitseuq
-ﺿﺮﻳﺐ ﺁﻟﻔﺎﻱ ﻛﺮﻭﻧﺒﺎﺥ ﺑﺮﺍﻱ ﻧﺴﺨﻪ. ﺁﺳﺎﻥ ﺍﺯ ﻣﺮﺍﺟﻌﻴﻦ ﺑﻪ ﻛﻠﻴﻨﻴﻚ ﺍﺧﺘﻼﻻﺕ ﺣﺮﻛﺘﻲ ﺍﻧﺘﺨﺎﺏ ﺷﺪﻩ ﺑﻮﺩﻧﺪ، ﻣﻮﺭﺩ ﺑﺮﺭﺳﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺖ
ﻫﺎﻱ ﺟﺎﻳﮕﺰﻳﻨﻲ ﺁﻳﺘﻢ. ﺎﺳﺒﻪ ﮔﺮﺩﻳﺪﻣﺤ 0/047%( 59ﺣﺪﻭﺩ ﺍﻃﻤﻴﻨﺎﻥ : 0/166-0/608)ﻣﻌﺎﺩﻝ  8-QDPﻱ ﻱ ﻓﺎﺭﺳﻲ ﭘﺮﺳﺸﻨﺎﻣﻪ
-QDP(ﻱ ﺍﺻﻠﻲ ﻛﻪ ﺩﺍﺭﺍﻱ ﺑﺎﻻﺗﺮﻳﻦ ﻫﻤﺒﺴﺘﮕﻲ ﺩﺭﻭﻧﻲ ﺩﺭ ﻫﺮ ﺑﻌﺪ ﻣﺤﺘﻮﺍﻳﻲ ﭘﺮﺳﺸﻨﺎﻣﻪ ﺑﺎ ﺳﻮﺍﻻﺗﻲ ﺩﻳﮕﺮ 8-QDPﻱ ﭘﺮﺳﺸﻨﺎﻣﻪ
ﻱ ﻱ ﭘﺮﺳﺸﻨﺎﻣﻪﻱ ﻓﺎﺭﺳﻲ ﻭ ﻛﻮﺗﺎﻩ ﺷﺪﻩﺩﺭ ﺍﻳﻦ ﭘﮋﻭﻫﺶ، ﻧﺴﺨﻪ. ﻧﮕﺮﺩﻳﺪ 8-QDPﻱ ﺑﻮﺩﻧﺪ ﻣﻨﺠﺮ ﺑﻪ ﺍﺭﺗﻘﺎﻱ ﭘﺎﻳﺎﻳﻲ ﭘﺮﺳﺸﻨﺎﻣﻪ )93
ﻫﺎﻱ ﺭﻭﺍﻧﻲ ﻭ ﺭﻓﺘﺎﺭﻱ ﺩﺭ ﻭﻳﮋﻩ ﺩﺭ ﺟﻨﺒﻪﻥ ﻳﻚ ﺍﺑﺰﺍﺭ ﻣﻌﺘﺒﺮ ﻭ ﭘﺎﻳﺎ ﺑﺮﺍﻱ ﺳﻨﺠﺶ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﺑﻪﻋﻨﻮﺍﺑﻪ 8-QDP
ﻋﻨﻮﺍﻥ ﻳﻚ ﺍﺑﺰﺍﺭ ﻛﺎﺭﺑﺮﺩﻱ ﺩﺭ ﻣﻌﺎﻳﻨﺎﺕ ﺭﻭﺗﻴﻦ ﺗﻮﺍﻧﺪ ﺑﻪﻱ ﻛﻮﺗﺎﻩ ﻣﻲﺍﻳﻦ ﭘﺮﺳﺸﻨﺎﻣﻪ. ﺑﻴﻤﺎﺭﺍﻥ ﺍﻳﺮﺍﻧﻲ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻣﻌﺮﻓﻲ ﺷﺪ
ﻋﻠﺖ ﻛﻮﺗﺎﻫﻲ ﺯﻣﺎﻥ ﻧﻴﺎﺯﻣﻨﺪ ﺍﺑﺰﺍﺭﻱ ﻣﺨﺘﺼﺮ ﻭ ﺩﻗﻴﻖ ﺑﺮﺍﻱ ﺳﻨﺠﺶ ﻛﻴﻔﻴﺖ ﻚ ﺑﻪﻛﻪ ﭘﺰﺷﺑﺎﻟﻴﻨﻲ ﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻭ ﻫﻨﮕﺎﻣﻲ
 .             ﺯﻧﺪﮔﻲ ﺑﻴﻤﺎﺭﺍﻥ ﺍﺳﺖ ﻣﻮﺭﺩ ﺍﺳﺘﻔﺎﺩﻩ ﻗﺮﺍﺭ ﺑﮕﻴﺮﺩ
ﺳﻮﺍﻝ  52ﻱ ﺟﺎﻣﻌﻲ ﻣﺸﺘﻤﻞ ﺑﺮ ﺑﺮﺍﻱ ﺳﺎﺧﺘﻦ ﺍﺑﺰﺍﺭ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺟﺪﻳﺪ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺩﺭ ﻣﻄﺎﻟﻌﺎﺕ ﺟﻤﻌﻴﺘﻲ، ﭘﺮﺳﺸﻨﺎﻣﻪ: 2ﭘﮋﻭﻫﺶ 
ﺑﺎ ﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ . ﻓﺮﺩ ﺷﺎﻫﺪ ﺗﻜﻤﻴﻞ ﮔﺮﺩﻳﺪ 011ﻓﺮﺩ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﻭ  751ﺍﻳﻦ ﺑﻴﻤﺎﺭﻱ ﺩﺭ  ﺍﺳﺘﺎﻧﺪﺍﺭﺩ ﺩﺭ ﻣﻮﺭﺩ ﻋﻼﻳﻢ ﻣﺨﺘﻠﻒ
ﺗﺮﻣﻮﺭ ﻭ "، "ﺳﻔﺘﻲ ﻭ ﺭﻳﮋﻳﺪﻳﺘﻲ ﻋﻀﻼﻧﻲ": ﺷﺶ ﻋﻼﻣﺖ ﺷﺎﻣﻞ )IUC( xednI ytilitU lacinilCﺑﺎﻟﻴﻨﻲ ﻳﺎ  ﺍﻳﻲﺷﺎﺧﺺ ﻛﺎﺭ
ﺍﺣﺴﺎﺱ ﭼﺴﺒﻴﺪﻥ ﭘﺎﻫﺎ ﺑﻪ "، "ﺭﺍﻩ ﺭﻓﺘﻦ ﻫﺎ ﺩﺭ ﺣﻴﻦﺍﺷﻜﺎﻝ ﺩﺭ ﺣﺮﻛﺎﺕ ﻫﻤﺎﻫﻨﮓ ﺩﺳﺖ"، "ﻫﺎﺍﺷﻜﺎﻝ ﺩﺭ ﺑﺴﺘﻦ ﺩﮔﻤﻪ"، "ﻟﺮﺯﺵ
ﺑﺮﺍﻱ ﺍﻧﺘﺨﺎﺏ ﺟﻬﺖ ﻏﺮﺑﺎﻟﮕﺮﻱ ( IUC ≥0/46)ﻫﺎ ﺑﺎ ﺍﻋﺘﺒﺎﺭ ﺧﻮﺏ ﻋﻨﻮﺍﻥ ﺑﻬﺘﺮﻳﻦ ﺁﻳﺘﻢﺑﻪ "ﻫﺎﻱ ﺭﻭﺯﻣﺮﻩﻛﻨﺪﻱ ﻓﻌﺎﻟﻴﺖ"ﻭ  "ﺯﻣﻴﻦ
ﻏﺮﺑﺎﻟﮕﺮﻱ ﺟﺪﻳﺪ ﺑﺮﺍﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﮔﺮﺩﻳﺪ ﻛﻪ ﺩﺭ  ﻱﺍﻳﻦ ﭘﮋﻭﻫﺶ ﻣﻨﺠﺮ ﺑﻪ ﻣﻌﺮﻓﻲ ﻳﻚ ﭘﺮﺳﺸﻨﺎﻣﻪ. ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﻣﻌﺮﻓﻲ ﺷﺪﻧﺪ
ﺗﻮﺍﻧﺪ ﺩﺭ ﺍﻳﻦ ﺍﺑﺰﺍﺭ ﻣﻲ. ﺭﺍ ﻧﺸﺎﻥ ﺩﺍﺩ( evruC rednU aerA =0/779)ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﻣﻮﺍﺭﺩ ﻣﺸﺎﺑﻪ ﻗﺒﻠﻲ ﺑﻬﺘﺮﻳﻦ ﺍﺭﺯﺵ ﺗﺸﺨﻴﺼﻲ 
ﺭﻱ ﻣﻮﺭﺩ ﻫﺎﻱ ﺛﺒﺖ ﺑﻴﻤﺎﻭﻳﮋﻩ ﺩﺭ ﺟﻮﺍﻣﻊ ﻓﺎﻗﺪ ﻧﻈﺎﻡﺑﻪﻱ ﺍﻓﺮﺍﺩ ﻣﺸﻜﻮﻙ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﻣﻄﺎﻟﻌﺎﺕ ﺟﻤﻌﻴﺘﻲ ﺑﺮﺍﻱ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺍﻭﻟﻴﻪ
       . ﺍﺳﺘﻔﺎﺩﻩ ﻗﺮﺍﺭ ﮔﻴﺮﺩ
ﻱ ﻱ ﺷﻬﺮﻱ ﺗﻬﺮﺍﻥ ﻭ ﺍﺯ ﻃﺮﻳﻖ ﺷﺒﻜﻪﻣﻨﻄﻘﻪ 22ﺍﻱ ﺍﺯ ﺧﺎﻧﻮﺍﺭﻫﺎﻱ ﺳﺎﻛﻦ ﺩﺭ ﺗﻤﺎﻡ ﮔﻴﺮﻱ ﺗﺼﺎﺩﻓﻲ ﭼﻨﺪ ﻣﺮﺣﻠﻪﻃﻲ ﻧﻤﻮﻧﻪ: 3ﭘﮋﻭﻫﺶ 
ﻟﻴﺴﺖ ﺍﻃﻼﻋﺎﺕ ﺩﺭ ﻫﺮ ﻳﻚ ﺍﺯ ﺍﻓﺮﺍﺩ ﭼﻚ. ﻓﺮﺩ ﻣﻮﺭﺩ ﺑﺮﺭﺳﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺘﻨﺪ 12602ﻭﺍﺣﺪ،  ﺗﻌﺪﺍﺩ  473ﻫﺎﻱ ﺳﻼﻣﺖ ﻣﺤﻠﻪ ﺷﺎﻣﻞ ﺧﺎﻧﻪ
 00591ﻫﺎﻱ ﻣﺮﺑﻮﻁ ﺑﻪ ﮔﺮﺩﻳﺪ ﻭ ﺩﺭ ﻧﻬﺎﻳﺖ ﺩﺍﺩﻩﺗﻜﻤﻴﻞ ﻣﻲ 2ﭘﮋﻭﻫﺶ ﻱ ﺟﺪﻳﺪ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺳﺎﺧﺘﻪ ﺷﺪﻩ ﺩﺭ ﺍﻱ ﻭ ﭘﺮﺳﺸﻨﺎﻣﻪﻪﺯﻣﻴﻨ
ﻧﻔﺮ ﻣﺸﻜﻮﻙ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺷﺪﻧﺪ ﻛﻪ ﺑﺮ  751ﭘﺲ ﺍﺯ ﺑﺮﺭﺳﻲ، . ﺳﺎﻝ ﻣﻮﺭﺩ ﺁﻧﺎﻟﻴﺰ ﻧﻬﺎﻳﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺖ 03<ﻧﻔﺮ ﺑﺎ ﺳﻦ 
ﺣﺪﻭﺩ ﺍﻃﻤﻴﻨﺎﻥ : 061-003)ﺳﻨﻲ ﻭ ﺟﻨﺴﻲ ﺩﺭ ﺟﻤﻌﻴﺖ ﻭﺍﻗﻌﻲ ﺗﻬﺮﺍﻥ ﻣﻌﺎﺩﻝ ﺍﻳﻦ ﺍﺳﺎﺱ ﺷﻴﻮﻉ ﺍﺳﺘﺎﻧﺪﺍﺭﺩ ﺷﺪﻩ ﺑﺮ ﻣﺒﻨﺎﻱ ﺗﻮﺯﻳﻊ 
 042-923)ﻣﻌﺎﺩﻝ ")OHW(ﺟﻤﻌﻴﺖ ﺍﺳﺘﺎﻧﺪﺍﺭﺩ ﺳﺎﺯﻣﺎﻥ ﺟﻬﺎﻧﻲ ﺑﻬﺪﺍﺷﺖ "ﻧﻔﺮ ﻭ ﺑﺮ ﻣﺒﻨﺎﻱ  000001ﺩﺭ ﻫﺮ  222/9%( 59
ﻱ ﺯﻥ ﺩﺭ ﺍﻓﺮﺍﺩ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺷﺪﻩ/ﻧﺴﺒﺖ ﺟﻨﺴﻲ ﻣﺮﺩ. ﻧﻔﺮ ﺗﺨﻤﻴﻦ ﺯﺩﻩ ﺷﺪ 000001ﺩﺭ ﻫﺮ  582%( 59ﺣﺪﻭﺩ ﺍﻃﻤﻴﻨﺎﻥ :
ﺷﻴﻮﻉ ﺗﺨﻤﻴﻦ ﺯﺩﻩ ﺷﺪﻩ . ﻳﺎﻓﺖﺻﻮﺭﺕ ﭘﻴﻮﺳﺘﻪ ﺑﺎ ﺑﺎﻻ ﺭﻓﺘﻦ ﮔﺮﻭﻩ ﺳﻨﻲ ﺍﻓﺰﺍﻳﺶ ﻣﻲﺑﻮﺩ ﻭ ﺷﻴﻮﻉ ﺑﻪ 1/26ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺍﺣﺘﻤﺎﻟﻲ 
ﺑﺮﺍﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺍﺣﺘﻤﺎﻟﻲ ﺩﺭ ﺍﻳﻦ ﭘﮋﻭﻫﺶ ﺑﻪ ﺁﻣﺎﺭﻫﺎﻱ ﺑﺮﺧﻲ ﻛﺸﻮﺭﻫﺎﻱ ﺍﺭﻭﭘﺎﻳﻲ ﻭ ﺧﺎﻭﺭﻣﻴﺎﻧﻪ ﻧﺰﺩﻳﻚ ﺑﻮﺩﻩ ﻭﻟﻲ ﺍﺯ ﮔﺰﺍﺭﺷﺎﺕ 
ﺩﺭ ﻫﺮ  002<ﻫﺮ ﺭﻭﻱ ﻧﺮﺥ ﺷﻴﻮﻉ ﺑﻪ . ﺗﺮ ﺍﺳﺖﺑﺎﻻﺗﺮ ﻭ ﺍﺯ ﺑﺮﺁﻭﺭﺩﻫﺎ ﺩﺭ ﺍﺳﺘﺮﺍﻟﻴﺎ ﭘﺎﻳﻴﻦﺷﻴﻮﻉ ﺩﺭ ﻛﺸﻮﺭﻫﺎﻱ ﺁﺳﻴﺎﻱ ﺷﺮﻗﻲ ﻭ ﺁﻓﺮﻳﻘﺎﻳﻲ 
              .  ﺷﻮﺩﺑﺎﻻ ﺩﺭ ﻧﻈﺮ ﮔﺮﻓﺘﻪ ﻣﻲ-ﺑﻪ-ﻋﻨﻮﺍﻥ ﺷﻴﻮﻋﻲ ﻣﺘﻮﺳﻂﻧﻔﺮ ﺑﺮﺍﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺩﺭ ﻧﻮﺍﺣﻲ ﺷﻬﺮﻱ ﺗﻬﺮﺍﻥ ﺩﺭ ﺍﻳﺮﺍﻥ ﺑﻪ 000001
  
ﻓﺮﺩ ﺷﺎﻫﺪ ﺟﻮﺭ ﺷﺪﻩ ﺍﺯ ﻧﻈﺮ ﺳﻦ ﻭ ﺟﻨﺲ ﺑﺎ  541ﺭﻛﻴﻨﺴﻮﻥ ﻭ ﺑﻴﻤﺎﺭ ﺍﻳﺮﺍﻧﻲ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎ 341ﺍﻱ ﺩﺭ ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ: 4ﭘﮋﻭﻫﺶ 
ﻣﻮﺭﺩ ﻣﻘﺎﻳﺴﻪ ﻗﺮﺍﺭ  )ANM( tnemssessA lanoitirtuN-iniMﻱ ﻱ ﭘﺮﺳﺸﻨﺎﻣﻪﻱ ﻓﺎﺭﺳﻲ ﻭ ﻣﻌﺘﺒﺮ ﺷﺪﻩﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ ﻧﺴﺨﻪ
 52/1( DS=3/4: )ﺩﺭ ﮔﺮﻭﻩ ﺑﻴﻤﺎﺭﺍﻥ]ﺑﻴﻦ ﺩﻭ ﮔﺮﻭﻩ ﻭﺟﻮﺩ ﻧﺪﺍﺷﺖ  ANMﺩﺍﺭﻱ ﺩﺭ ﻣﻴﺎﻧﮕﻴﻦ ﺍﻣﺘﻴﺎﺯ ﻛﻠﻲ ﺗﻔﺎﻭﺕ ﺁﻣﺎﺭﻱ ﻣﻌﻨﻲ. ﮔﺮﻓﺖ
%( 52/9)ﻧﻔﺮ  73ﺑﺎ ﺳﻮء ﺗﻐﺬﻳﻪ ﻭ %( 2/1)ﻧﻔﺮ  3ﺩﺭ ﮔﺮﻭﻩ ﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ  ([.p=0/490)، 42/4( DS=3/8: )ﻭ ﺩﺭ ﮔﺮﻭﻩ ﺷﺎﻫﺪ
-ﻫﺮ ﭼﻨﺪ ﻧﺘﺎﻳﺞ ﺍﻳﻦ ﭘﮋﻭﻫﺶ ﺑﻪ(. p=0/822)ﺩﺍﺭﻱ ﺑﺎ ﮔﺮﻭﻩ ﺷﺎﻫﺪ ﻧﺪﺍﺷﺖ ﺑﺎ ﺧﻄﺮ ﺳﻮء ﺗﻐﺬﻳﻪ ﺷﻨﺎﺳﺎﻳﻲ ﺷﺪﻧﺪ ﻛﻪ ﺍﻟﺒﺘﻪ ﺗﻔﺎﻭﺕ ﻣﻌﻨﻲ
ﻭ ﮔﺮﻭﻩ ﺷﺎﻫﺪ  ﺑﺎ ﺷﺪﺕ ﺧﻔﻴﻒ ﺗﺎ ﻣﺘﻮﺳﻂ ﺍﻱ ﻣﺸﺎﺑﻬﻲ ﺑﻴﻦ ﺑﻴﻤﺎﺭﺍﻥ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥﻳﻪﻱ ﻭﺿﻌﻴﺖ ﺗﻐﺬﺩﻫﻨﺪﻩﻃﻮﺭ ﻛﻠﻲ ﻧﺸﺎﻥ
ﺍﻱ ﺑﻮﺩﻧﺪ ﻛﻪ ﻟﺰﻭﻡ ﺗﻮﺟﻪ ﺑﻴﺸﺘﺮ ﺑﻪ ﺍﺭﺯﻳﺎﺑﻲ ﻧﻮﻋﻲ ﺩﭼﺎﺭ ﻣﺸﻜﻞ ﺗﻐﺬﻳﻪﺑﻮﺩ، ﺑﺎﻳﺪ ﺩﺭ ﻧﻈﺮ ﺩﺍﺷﺖ ﻛﻪ ﻧﺰﺩﻳﻚ ﺑﻪ ﻳﻚ ﺳﻮﻡ ﺑﻴﻤﺎﺭﺍﻥ ﺑﻪ
        .   ﺩﻫﺪﺍﻱ ﺍﻓﺮﺍﺩ ﻣﺒﺘﻼ ﺑﻪ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺭﺍ ﻧﺸﺎﻥ ﻣﻲﺗﻐﺬﻳﻪ
ﺑﻴﻤﺎﺭ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺑﺎ ﺍﺭﺯﻳﺎﺑﻲ ﺟﺎﻣﻌﻲ ﺍﺯ ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ ﻭ ﻏﻴﺮ  051ﺍﻱ ﺩﺭ ﻋﻮﺍﻣﻞ ﻣﻮﺛﺮ ﺑﺮ ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ: 5ﭘﮋﻭﻫﺶ 
 s’nosnikraP deifinUﻱ ﻛﻠﻲ ﻣﻘﻴﺎﺱ ﺟﺎﻣﻊ ﺍﻣﺘﻴﺎﺯﮔﺬﺍﺭﻱ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻳﺎ ﻧﻤﺮﻩ. ﺣﺮﻛﺘﻲ ﻣﻮﺭﺩ ﺑﺮﺭﺳﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺖ
( r= -0/482، p=0/200) ﻭ ﻣﺪﺕ ﺯﻣﺎﻥ ﺍﺑﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ( r= -0/316، p<0/100) )SRDPU( elacs gnitar esaesid
ﻱ ﺩﺍﺭﻱ ﺩﺭ ﻣﺮﺣﻠﻪﻃﻮﺭ ﻣﻌﻨﻲﺍﻱ ﺑﻪﺑﻴﻤﺎﺭﺍﻥ ﺩﭼﺎﺭ ﻋﺪﻡ ﻛﻔﺎﻳﺖ ﺗﻐﺬﻳﻪ. ﺩﺍﺷﺘﻨﺪ ANMﻱ ﻛﻠﻲ ﺩﺍﺭ ﻣﻌﻜﻮﺳﻲ ﺑﺎ ﻧﻤﺮﻩﻫﻤﺒﺴﺘﮕﻲ ﻣﻌﻨﻲ
، (5/9ﻣﻘﺎﺑﻞ ﺩﺭ  8/8، p=0/200)، ﺍﺿﻄﺮﺍﺏ (2/0ﺩﺭ ﻣﻘﺎﺑﻞ  2/5، p<0/100) egats rhaY dna nheoHﺑﺎﻻﺗﺮ ﺑﻴﻤﺎﺭﻱ ﺑﺎ 
ﺩﺭ ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﺑﻴﻤﺎﺭﺍﻥ ﺩﺍﺭﺍﻱ ( 4/2ﺩﺭ ﻣﻘﺎﺑﻞ  5/4، p<0/100)ﻭ ﺧﺴﺘﮕﻲ ﺷﺪﻳﺪﺗﺮﻱ ( 3/6ﺩﺭ ﻣﻘﺎﺑﻞ  9/0، p<0/100)ﺍﻓﺴﺮﺩﮔﻲ 
ﺩﺍﺭﻱ ﺑﺎ ﺍﻣﺘﻴﺎﺯ ﻛﻠﻲ ﻃﻮﺭ ﻣﻌﻨﻲﻫﺎﻱ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﺑﻪﺟﺰ ﺍﺳﺘﻴﮕﻤﺎ، ﺳﺎﻳﺮ ﺣﻴﻄﻪﺑﻪ. ﺍﻱ ﻣﻨﺎﺳﺐ ﺑﻮﺩﻧﺪﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ
ﺍﻱ ﺍﺯ ﻋﻼﻳﻢ ﺍﻳﻦ ﭘﮋﻭﻫﺶ ﻧﺸﺎﻥ ﺩﺍﺩ ﻣﺪﺕ ﺯﻣﺎﻥ ﺑﻴﻤﺎﺭﻱ، ﺷﺪﺕ ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ ﻭ ﻃﻴﻒ ﮔﺴﺘﺮﺩﻩ ﻧﺘﺎﻳﺞ. ﺍﺭﺗﺒﺎﻁ ﺩﺍﺷﺖ ANM
ﻃﻮﺭ ﻗﺎﺑﻞ ﺗﻮﺟﻬﻲ ﻛﻴﻔﻴﺖ ﺗﻮﺍﻧﺪ ﺑﻪﺑﺎﺷﺪ ﻛﻪ ﻣﻲﺍﻱ ﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻣﺮﺗﺒﻂ ﻣﻲﻏﻴﺮﺣﺮﻛﺘﻲ ﻭ ﺭﻭﺍﻧﺸﻨﺎﺧﺘﻲ ﺑﺎ ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ
         .     ﺍﺭ ﺩﻫﺪﻭﻳﮋﻩ ﺍﺣﺴﺎﺳﻲ ﻭ ﺣﺮﻛﺘﻲ ﺗﺤﺖ ﺗﺎﺛﻴﺮ ﻗﺮﻫﺎﻱ ﻣﺨﺘﻠﻒ ﺑﻪﺯﻧﺪﮔﻲ ﺑﻴﻤﺎﺭﺍﻥ ﺭﺍ ﺩﺭ ﺟﻨﺒﻪ
ﻣﻨﺎﺳﺐ ﺑﺮﺍﻱ ﺍﻟﮕﻮﻱ  )MES( gniledoM noitauqE larutcurtSﻣﻨﻈﻮﺭ ﺩﺳﺘﻴﺎﺑﻲ ﺑﻪ ﻣﺪﻝ ﺳﺎﺧﺘﺎﺭﻱ ﻳﺎ ﺑﻪ: 6ﭘﮋﻭﻫﺶ 
-ﺍﻱ ﻭ ﺑﻴﻤﺎﺭﻱﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ)ﺍﻱ ﻫﺎﻱ ﺯﻣﻴﻨﻪﺍﻱ ﺍﺯ ﻭﻳﮋﮔﻲﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﺩﺭ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ، ﻃﻴﻒ ﮔﺴﺘﺮﺩﻩ
ﺑﻴﻤﺎﺭ  751ﺩﺭ ( ﺍﺟﺘﻤﺎﻋﻲ-ﻋﻼﻳﻢ ﺭﻭﺍﻧﺸﻨﺎﺧﺘﻲ، ﺧﺴﺘﮕﻲ، ﻋﻤﻠﻜﺮﺩ ﺭﻭﺍﻧﻲ)ﻭ ﻏﻴﺮﺣﺮﻛﺘﻲ ( SRDPU)، ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ (ﺍﻱﻫﺎﻱ ﺯﻣﻴﻨﻪ
ﺩﺭ ﺁﻧﺎﻟﻴﺰ . ﻫﺎﻱ ﺍﺳﺘﺎﻧﺪﺍﺭﺩ ﻭ ﻣﻌﺎﻳﻨﺎﺕ ﺑﺎﻟﻴﻨﻲ ﻣﻮﺭﺩ ﺍﺭﺯﻳﺎﺑﻲ ﻗﺮﺍﺭ ﮔﺮﻓﺖﻫﺎﻱ ﻣﻌﺘﺒﺮ، ﻣﻘﻴﺎﺱﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺗﻮﺳﻂ ﭘﺮﺳﺸﻨﺎﻣﻪ
ﻓﺎﻛﺘﻮﺭﻫﺎﻱ ﺗﺎﺛﻴﺮﮔﺬﺍﺭ ﻣﺴﺘﻘﻞ ﺑﺮ  II trap-SRDPUﻱ ﻱ ﺭﮔﺮﺳﻴﻮﻧﻲ، ﺟﻨﺴﻴﺖ ﺯﻥ، ﺍﺿﻄﺮﺍﺏ، ﺍﻓﺴﺮﺩﮔﻲ ﻭ ﻧﻤﺮﻩﭼﻨﺪﻣﺘﻐﻴﺮﻩ
ﻣﺪﻝ ﻣﻌﺘﺒﺮ . ﺷﻨﺎﺧﺘﻪ ﺷﺪﻧﺪ )ISDP( xedni ytireves esaesid s’nosnikraPﺷﺎﺧﺺ ﺷﺪﺕ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﻳﺎ 
ﺍﺯ ﺗﻐﻴﻴﺮﺍﺕ % 98ﻫﺎﻱ ﻫﻤﺮﺍﻩ ﻣﻮﻓﻖ ﺑﻪ ﭘﻴﺸﮕﻮﻳﻲ ﺷﺎﻣﻞ ﻧﺸﺎﻧﮕﺮﻫﺎﻱ ﺟﺎﻣﻌﻲ ﺑﺮﺍﻱ ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ، ﻏﻴﺮﺣﺮﻛﺘﻲ ﻭ ﺑﻴﻤﺎﺭﻱ MES
ﻫﺎﻱ ﻣﺨﺘﻠﻒ ﻛﻪ ﺍﻳﻦ ﻣﺪﻝ ﺳﺎﺧﺘﺎﺭﻱ ﺩﺭ ﺯﻳﺮ ﮔﺮﻭﻩﺁﻥﺟﺎﻟﺐ . ﺑﺎ ﺳﻼﻣﺖ ﺩﺭ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﮔﺮﺩﻳﺪ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ
ﻗﺎﺑﻞ ﺗﻮﺟﻪ ﺑﻴﻦ  ﻱ ﻣﺘﻔﺎﻭﺗﻲ ﺩﺍﺷﺖ ﻛﻪ ﺑﻴﺎﻧﮕﺮ ﻧﺎﻫﻤﮕﻮﻧﻲﻛﻨﻨﺪﻩﻫﺎﻱ ﻣﺘﻔﺎﻭﺕ، ﺍﻟﮕﻮﻫﺎ ﻭ ﻋﻮﺍﻣﻞ ﺗﻌﻴﻴﻦﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺑﺎ ﻓﻨﻮﺗﻴﭗ
 .ﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺍﺳﺖ
ﺑﺎﻻ ﺑﺮﺍﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻧﻴﺴﻢ ﺍﺣﺘﻤﺎﻟﻲ ﺩﺭ ﺟﻤﻌﻴﺖ ﺍﻳﺮﺍﻧﻲ ﺳﺎﻛﻦ ﺩﺭ ﻣﻨﺎﻃﻖ ﺷﻬﺮﻱ -ﺑﻪ-ﺘﻮﺳﻂﺩﺭ ﺍﻳﻦ ﭘﺮﻭژﻩ ﺷﻴﻮﻋﻲ ﻣ: ﮔﻴﺮﻱﻧﺘﻴﺠﻪ
ﺍﻱ ﺑﻴﻤﺎﺭﺍﻥ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺑﺎ ﺷﺪﺕ ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ. ﺗﻬﺮﺍﻥ ﺑﺎ ﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ ﻳﻚ ﺍﺑﺰﺍﺭ ﻏﺮﺑﺎﻟﮕﺮﻱ ﺟﺪﻳﺪ ﻭ ﻣﻌﺘﺒﺮ ﻧﺸﺎﻥ ﺩﺍﺩﻩ ﺷﺪ
ﺭﻏﻢ ﺷﺪﺕ ﺎﻝ، ﻧﺰﺩﻳﻚ ﺑﻪ ﻳﻚ ﺳﻮﻡ ﺍﻳﻦ ﺑﻴﻤﺎﺭﺍﻥ ﻋﻠﻲﺣﺑﺎ ﺍﻳﻦ. ﻣﺘﻮﺳﻂ ﺑﺎ ﮔﺮﻭﻩ ﺷﺎﻫﺪ ﺟﻮﺭ ﺷﺪﻩ ﺍﺯ ﻫﻤﺎﻥ ﺟﺎﻣﻌﻪ ﻣﺸﺎﺑﻪ ﺑﻮﺩ-ﺗﺎ-ﺧﻔﻴﻒ
ﻣﺪﺕ ﺯﻣﺎﻥ ﺑﻴﻤﺎﺭﻱ، ﺷﺪﺕ ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ، ﺍﻓﺴﺮﺩﮔﻲ، ﺍﺿﻄﺮﺍﺏ . ﻧﺴﺒﺘﺎ ﻛﻢ ﺑﻴﻤﺎﺭﻱ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺩﺭ ﻣﻌﺮﺽ ﺳﻮء ﺗﻐﺬﻳﻪ ﻗﺮﺍﺭ ﺩﺍﺷﺘﻨﺪ
ﻫﺎﻱ ﻫﻤﭽﻨﻴﻦ ﻋﻼﻳﻢ ﺣﺮﻛﺘﻲ ﻣﻮﺛﺮ ﺑﺮ ﻓﻌﺎﻟﻴﺖ. ﺍﻱ ﺩﺭ ﺑﻴﻤﺎﺭﺍﻥ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺩﺭ ﺍﺭﺗﺒﺎﻁ ﺑﻮﺩﻭ ﺧﺴﺘﮕﻲ ﺑﺎ ﻭﺿﻌﻴﺖ ﺗﻐﺬﻳﻪ
ﺗﺮﻳﻦ ﻋﻮﺍﻣﻠﻲ ﻛﻪ ﻣﺴﺘﻘﻼ ﺑﺮ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﺩﺭ ﺑﻴﻤﺎﺭﺍﻥ ﻋﻨﻮﺍﻥ ﻗﻮﻱﺭﻭﺯﻣﺮﻩ، ﺟﻨﺴﻴﺖ ﺯﻥ، ﺍﻓﺴﺮﺩﮔﻲ ﻭ ﺍﺿﻄﺮﺍﺏ ﺑﻪ
ﻱ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﻛﻨﻨﺪﻩﻧﺎﻫﻤﮕﻮﻧﻲ ﺁﺷﻜﺎﺭﻱ ﺩﺭ ﺍﻟﮕﻮﻫﺎ ﻭ ﻋﻮﺍﻣﻞ ﺗﻌﻴﻴﻦ. ﮔﺬﺍﺭﻧﺪ، ﺷﻨﺎﺧﺘﻪ ﺷﺪﻧﺪﺍﻳﺮﺍﻧﻲ ﻣﺒﺘﻼ ﺑﻪ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺗﺎﺛﻴﺮ ﻣﻲ
ﺑﺎﻳﺴﺖ ﺩﺭ ﺍﺭﺯﻳﺎﺑﻲ، ﺭﻭﻧﺪ ﺩﺭﻣﺎﻥ ﻭ ﺍﻳﻦ ﻫﺘﺮﻭژﻧﻴﺘﻲ ﻣﻲ. ﻫﺎﻱ ﻣﺨﺘﻠﻒ ﺩﻳﺪﻩ ﺷﺪﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺑﺎ ﻓﻨﻮﺗﻴﭗ ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ ﺩﺭ ﺑﻴﻤﺎﺭﺍﻥ
ﻫﺎ ﻭ ﻋﻼﻳﻢ ﻣﺨﺘﻠﻒ ﻣﺪ ﻧﻈﺮ ﻗﺮﺍﺭ ﮔﻴﺮﺩ ﺗﺎ ﺳﺎﻳﺮ ﻣﺪﺍﺧﻼﺕ ﺑﺮﺍﻱ ﺍﺭﺗﻘﺎﻱ ﻋﻼﻳﻢ ﻭ ﻛﻴﻔﻴﺖ ﺯﻧﺪﮔﻲ ﺑﻴﻤﺎﺭﺍﻥ ﭘﺎﺭﻛﻴﻨﺴﻮﻥ ﺑﺎ ﻓﻨﻮﺗﻴﭗ
    .ﺩﺭ ﻫﺮ ﻳﻚ ﺍﺯ ﺑﻴﻤﺎﺭﺍﻥ ﺷﻮﺩ( hcaorppa dezilanosreP)ﻫﺎﻱ ﺍﻧﻔﺮﺍﺩﻱ ﻣﻮﺛﺮ ﻛﺎﺭﮔﻴﺮﻱ ﺭﻭﺵﺳﺮﺍﻧﺠﺎﻡ ﻣﻨﺠﺮ ﺑﻪ ﺗﻜﺎﻣﻞ ﻭ ﺑﻪ
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1 INTRODUCTION 
1.1 Parkinson’s disease 
1.1.1 Definitions and diagnostic criteria 
Parkinson’s disease (PD) is considered as the major neurodegenerative movement disorder 
conventionally characterized by its cardinal motor symptoms namely bradykinesia, resting 
tremor, rigidity and postural instability [1]. The United Kingdom Brain Bank has introduced 
the following criteria for parkinsonian syndrome [2], which has long been used in both 
clinical practice and research projects as well: 
• “Bradykinesia 
• At least one of the following: 
o muscular rigidity 
o 4-6 Hz rest tremor 
o postural instability not caused by primary visual, vestibular, cerebellar, 
or proprioceptive dysfunction” [2] 
Recent profound changes in knowledge and improvements in the understanding of PD have 
emerged the International Parkinson and Movement Disorders Society (MDS) to 
commission a task force to redefine PD [3]. Increasingly more and more non-motor 
symptoms (NMS) such as psychiatric disorders, cognitive impairment, autonomic 
dysfunction, sleep disorders and sensory problems have been found to be associated with 
PD, some of which have been recognized as prodromal symptoms that might even appear 
before motor manifestations start [4]. Not only in symptomatology but also in 
pathophysiology of PD, new findings have deeply changed our previous knowledge such as 
genetic cases without synucleinopathy and rather considerable prevalence of incidental 
Lewy body (LB) deposition in elderly population [3]. Yet, the mainstay of PD definition is 
based on motor features and the MDS task force commission in 2014, highlighted clinical 
expertise as the gold standard for PD diagnosis, which consists of the following criteria [3]: 
• “A motor clinical syndrome, with levodopa-responsive parkinsonism, typical 
clinical characteristics, and the absence of markers suggestive of other disease 
• Pathologic confirmation of α-synuclein deposition and dopamine neuronal loss 
in the substantia nigra pars compacta (SNpc)” [3] 
1.1.2 Etiology and pathology 
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Idiopathic Parkinson’s disease (IPD), also called PD, is the most common type of a larger 
group of movement disorders called parkinsonism. About 30-40% of the patients with 
parkinsonism suffer from other types generally labeled as atypical parkinsonism (AP) [5-6]. 
Although these entities largely overlap in symptoms, different underlying pathologies are 
involved. Other than vascular and drug-induced parkinsonism and those with consequential 
disease following stroke, inflammation and intoxication, no clear single etiology has been 
found for other types of parkinsonism including the commonest one, IPD. A complex 
etiology has now been proposed consisting of both genetic and environmental factors. 
Some of the gene mutations that could cause PD both in familial and sporadic forms are α-
synuclein, Parkin, SNCA, UCHL1, DJ1, PINK1, GIGYF2 and LRRK2 [7-8], yet only 15% 
of the patients with PD have a positive history of parkinsonism in their first-degree relatives 
[9]. Among the environmental risk factors, some pesticides and chemicals such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [10], bacterial infections (Gardnerella 
vaginalis, Helicobacter jejuni) [8] and head injuries [11] have been proposed. Nevertheless, 
aging is well known as the strongest risk factor for development of PD [8].        
The hallmark of PD pathology is the accumulation of misfolded α-synuclein protein, its 
deposition and formation of the LBs in susceptible neurons, especially in the SNpc, which 
leads to the loss of dopaminergic neurons [12]. Death of dopaminergic neurons may itself 
initiates a cascade of adverse events namely energy crisis, oxidative stress, inflammatory 
reactions by glial cells, proteasomal abnormalities, finally protein aggregation and α-
synuclein deposition [8]. Nonetheless, PD has now been accepted as a progressive 
multiorgan disease with a comprehensive list of non-motor features indicating that non-
dopaminergic systems such as serotonergic and cholinergic are also involved in 
pathophysiology of the NMS [4, 13]. So far, different hypotheses have been proposed on 
how synucleinopathy starts, spreads and presents in PD pathophysiologic cascade. 
According to the Braak theory, LB pathology firstly involves the Meissner and Auerbach 
plexus of the foregut, then through a retrograde trans-synaptic transmission reaches the 
preganglionic parasympathetic motor neurons of the vagus nerve, spreads up to the 
olfactory bulb and medulla oblongata, then further up to substantia nigra and lastly to 
higher cortical levels [14-15]. This theory fairly corresponds to the chronicity of the 
symptoms in most PD patients starting from a non-motor prodromal phase, to motor 
manifestations and ending with developed emotional and cognitive dysfunctions (Figure 1). 
Furthermore, there are other proofs of concept such as the finding of neuronal synuclein 
deposition in 60–70% of the colon biopsies from PD patients [16].  
The "prion-like” hypothesis has been also proposed as a potential mechanism to explain the 
spreading of synucleinopathy in PD. Accordingly, pathogenic misfolded α-synuclein can be 
released by living neurons through exocytosis into the neighboring extracellular milieu, 
where it is then taken up by the intact nearby neurons via endocytosis. This exogenous α-
synuclein may act as a template that endorses misfolding of endogenous α-synuclein to 
ultimately form LB in the second chain of the neurons [17-18]. 
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Figure 1. Schematic illustration of the time-course and stages of Parkinson’s disease based 
on the Braak theory    
 
1.1.3 Symptomatology  
Regarding the multisystem nature of PD, a broad list of various symptoms could be 
presented, which are generally divided into two large categories: motor and non-motor 
symptoms. A brief classification of these symptoms can be presented as [1, 4, 16]: 
• Motor symptoms 
o cardinal motor features 
o other motor features 
!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!
Phase Symptoms Area 
 
Advanced  
(Late non-motor and motor 
symptoms) 
Emotional and 
cognitive 
disturbances 
 
Cortex 
 
Symptomatic  
(Motor and non-motor 
manifestations) 
Dyskinesia  
 
Substantia nigra 
Motor 
fluctuations 
Movement 
problems 
 
Prodromal 
(Early non-motor symptoms) 
Hyposmia Olfactory bulb 
 
Sleep 
disorders 
 
 
Brain stem 
 
Autonomic 
dysfunction 
 
Vagus nerve 
Constipation 
 
 
 
 
 
Enteric nervous 
plexuses of the 
foregut 
 
 
 
 
Time-course Disease stage 
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o drug-induced motor complications 
• Non-motor symptoms 
o pre-motor (prodromal) manifestations 
o early/middle stage non-motor manifestations 
o drug-induced non-motor side-effects 
o late/advanced stage non-motor manifestations 
 A more specific list of the symptoms is shown in Table 1.    
NMS are quite diverse in PD both in their presentation and timing. Although some 
particular symptoms are believed to occur during the long pre-motor prodromal period 
particularly impairment of olfaction, vagal dysfunction, constipation, and sleep disorders, 
they can also be observed during the early- and even the late-stage of the disease with 
different severities [16]. Dementia and psychosis are more likely to develop in later stages 
of PD, however, accumulating recent evidence suggests that mild cognitive impairment 
(MCI) and mood disorders could be found quite early in PD course as well [19]. Similarly, 
while fatigue and pain mainly dominate the clinical picture of PD during the advanced 
stages, they have been listed as prodromal NMS, too [4]. Nonetheless, there are some 
overall classifications as presented in Table 1.   
1.1.4 Prognosis and treatment 
PD is not a life-threatening disease by itself, but through some advanced complications 
such as serious falling, aspirations, deep vein thrombosis and pulmonary embolism in 
immobile late-stage patients. However, as a progressive neurodegeneration both motor and 
non-motor problems worsen throughout the course of the disease quite diversely. Disease 
progression varies largely from one patient to another and some dominant features have 
been shown to predict more rapid progression particularly MCI, orthostatic hypotension 
(OH) and REM sleep behavior disorder (RBD) [19]. A reduced death age has been shown 
in PD patients especially for the young-onset group [20]. However, in case of timely 
diagnosis and appropriate management, PD patients are expected to experience often about 
the same life expectancy as for the general population particularly among those who do not 
develop dementia [21].  
Exogenous supply of brain’s dopamine is the mainstay of PD medication, which has 
dramatically improved the management and control of movement problems. Levodopa in 
combination with carbidopa or benserazide, and dopamine agonists such as pramipexole, 
ropinirole, rotigotine and apomorphine are quite widely used to control motor symptoms. 
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Table 1. Symptomatology of Parkinson’s disease 
 
Type Classification Symptoms/Signs 
Motor 
Cardinal motor 
features 
§ Bradykinesia 
§ Resting tremor 
§ Rigidity 
§ Postural instability 
Other motor features 
§ Gait disturbances (shuffling gait, turning “en bloc”) 
§ Decreased arm-swing 
§ Micrographia (smaller hand-writing) 
§ Camptocormia (stooped posture) 
§ Festination 
§ Freezing of gait 
§ Falling 
§ Dystonia 
§ Scoliosis 
§ Hypomimia (masked face) 
§ Hypophonia (soft speech) 
§ Drooling 
§ Dysphagia (impaired swallowing) 
§ Dysarthria 
§ Difficulty rolling in bed 
§ Difficulty rising from a chair 
§ Impaired motor coordination 
§ Akathisia (unpleasant desire to move) 
§ Restless legs 
§ Reemergence of primitive reflexes 
§ Glabellar reflex 
Drug-induced motor 
complications 
§ Dyskinesia 
§ Motor fluctuations (wearing-off) 
 
Non-
motor 
Pre-motor 
(prodromal) 
manifestations 
§ Hyposmia (decreased sense of smelling) 
§ Rapid eye movement sleep behavior disorder (RBD) 
§ Constipation 
§ Depression 
§ Anxiety 
§ Excessive daytime sleepiness 
§ Fatigue 
§ Pain 
§ Erectile dysfunction 
Early/middle stage 
non-motor 
manifestations 
§ Mild cognitive impairment (MCI) (executive 
dysfunction, slowed cognitive speed, memory 
problems, problems in verbal fluency, difficulties in 
visuospatial skills) 
§ Color vision impairment and other neuro-
ophthalmological disorders (blurred vision, diplopia, 
decreased eye convergence, etc.) 
§ Hyposmia (decreased or loss of sense of smelling) 
§ Impaired proprioception 
§ Paresthesias 
§ Depression 
§ Anxiety 
§ Apathy 
§ Autonomic dysfunction [i.e. orthostatic hypotension 
(OH), supine hypertension, sexual disorder, oily 
skin, urinary incontinence, excessive sweating] 
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§ Constipation 
§ Sleep disorders (RBD, insomnia, daytime 
somnolence) 
Drug-induced non-
motor side-effects 
§ Impulse control disorders (ICD) (gambling, punding, 
compulsive buying, sexual behavior, and/or eating) 
§ Hallucination 
§ Dopamine agonist withdrawal syndrome 
§ Parkinson's hyperpyrexia syndrome 
(thermoregulatory failure, delirium) 
Late/advanced stage 
non-motor 
manifestations 
§ Pain 
§ Fatigue 
§ Depression 
§ Autonomic dysfunction [i.e. orthostatic hypotension 
(OH), supine hypertension, sexual disorder, oily 
skin, urinary incontinence, excessive sweating] 
§ Sleep disorders (RBD, insomnia, daytime sleepiness) 
§ Dementia 
Recently, duodopa extended-released gel has been approved for continuous intestinal 
administration of levodopa. MAO-B inhibitors namely selegiline and rasagiline and 
catechol o-methyltransferase (COMT) inhibitors such as entacapone are also helpful 
through the inhibition of the breakdown of dopamine. Other treatment options include 
anticholinergics, amantadine, and deep brain stimulation (DBS) as a surgical intervention in 
eligible patients [22]. Management of NMS is also crucial due to their high prevalence, 
huge burden and considerable effects on life quality in PD patients. There are several 
treatment options to handle NMS that are decided individually with respect to the types and 
severity of each NMS that a single patient might suffer from. Level I evidence is available 
to treat NMS in PD only for few of them including paroxetine and venlafaxine for 
depression [23], and modafinil for improving patients’ perception of wakefulness in 
daytime somnolence [24]. Other pharmacological recommendations include sildenafil 
citrate for erectile dysfunction, fludrocortisone for OH, cholinesterase inhibitors and 
memantine for dementia, methylphenidate for fatigue, oxycodone with naloxone for pain, 
clonazepam, melatonin and pramipexole for RBD, just to name a few [4]. Other than 
medications, a multidisciplinary team support consisting of a movement disorder specialist, 
geriatrician, specialist nurse, speech therapist, physiotherapist, occupational therapist and 
neuropsychiatrist is needed to efficiently tackle with a multisystem and multiorgan disease 
such as PD. In addition, appropriate timely palliative care is beneficial throughout the 
whole PD course particularly during the advanced stage of the disease [25-26]. 
      
1.2 Epidemiology of parkinsonism and Parkinson’s disease 
Findings from literature review on the prevalence of parkinsonism and PD are summarized 
in Table 2, which clearly shows that the rates vary widely between different ethnic groups 
and countries categorized according to the six World Health Organization (WHO) regions.  
1.2.1 Prevalence of parkinsonism 
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In one survey from the Aeolian Archipelago in Sicily, Italy, a prevalence rate of 
323.4/100,000 has been found for all types of parkinsonism in individuals aged 40 years 
and over [27]. In a record-based study conducted in north of Wales, United Kingdom, 
prevalence of parkinsonism has been reported as 122/100,000 [28]. In another study on 
Egyptian population aged >40 years, prevalence of parkinsonism was found to be 
316.5/100,000 [29]. Other few reports resulted in a quite broad estimation for the 
prevalence of parkinsonism ranging from 339.6/100,000 in Columbia [30] to 659.0/100,000 
in Egypt [31] and even as high as 800/100,000 in Albania [32].  
1.2.2 Prevalence and incidence of Parkinson’s disease  
The incidence of PD rises steeply with age, from 17.4 in 100,000 person aged between 50 
and 59 years to 93.1 in 100,000 person aged between 70 and 79 years, with a lifetime risk 
of developing the disease of 1.5% [33]. The median age of onset is 60 years and the mean 
duration of the disease from diagnosis to death is approximately 15 years [34]. Data on 
prevalence of PD is quite diverse as shown in Table 2. The crude prevalence rate has been 
estimated as low as 15 per 100,000 in China [35] to even as high as 850 per 100,000 in 
Caucasians [36]. In general, PD prevalence and incidence has been found to be lower in 
Afro-Americans, Japanese, and some other Asian countries [37]. In the Eastern 
Mediterranean region, data on PD prevalence is available from Egypt, Tunisia, Jordan and 
Saudi Arabia showing an estimated rate of 213.1/100,000 [29], 216.0/100,000 [38], 
58.8/100,000 [39] and 27.0/100,000 [40], respectively.  
1.2.3 Methodological issues 
Besides ethnical and environmental factors that contribute in the variation of PD prevalence 
across countries, methodological aspects of the surveys and data collections play an 
important role. More specifically, one must consider sampling method, source of data 
collection and standardization method that have been used on the crude prevalence rates for 
between-countries comparisons of neuroepidemiologic data. While in developed countries 
prevalence data could be easily obtained through electronic patients’ registries or drug 
tracing through the pharmacies, community-based door-to-door surveys are the most valid 
method of data collection in poor-resource developing countries. In a systematic review on 
studies published during 1965-2008 in Asian countries, the standardized prevalence of PD 
was shown to vary from 51.3 to 176.9/100,000 in community-based door-to-door surveys, 
while in record-based studies from the same geographical region the rate has been 
estimated to be generally lower ranging from 35.8 to 68.3/100,000 [41]. Population-based 
surveys such as door-to-door studies tend to overestimate PD prevalence through the 
ascertainment of undiagnosed cases some of which might be falsely screened, whereas 
record-based reports represent only diagnosed patients and definitely underestimate the real 
prevalence rates [42]. Yet, among population-based studies prevalence of PD is commonly 
higher in European and Eastern Mediterranean regions compared to the African and Eastern 
Asian countries (Table 2).    
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Table 2. Prevalence rate of Parkinson disease and/or parkinsonism using different data-collection and standardization methods in different 
countries from each of the six World Health Organization regions 
 
Country Continent WHO Region Condition Data Collection Method 
Standardization 
Method 
Prevalence 
(/100,000) Year 
Alaska North America Region of the Americas Parkinson's disease Record-Based 
Global 
Standardized 355.7 2009 
Canada North America Region of the Americas Parkinson's disease Record-Based Local Standardized 144.0 2003 
USA North America Region of the Americas Parkinson's disease Record-Based Local Standardized 107.0 1993 
USA North America Region of the Americas Parkinson's disease Record-Based 
Global 
Standardized 81.0 1995 
USA North America Region of the Americas Parkinson's disease Capture-recapture Local Standardized 329.3 2000 
Argentina Central/South America 
Region of the 
Americas Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 174.3 1997 
Bolivia Central/South America 
Region of the 
Americas Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 106.5 2003 
Brazil Central/South America 
Region of the 
Americas Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 297.7 2006 
Colombia Central/South America 
Region of the 
Americas Parkinson's disease 
Population-Based  
(door-to-door) No Standardization 470.0 1997 
Colombia Central/South America 
Region of the 
Americas Parkinsonism Capture-recapture No Standardization 339.6 2004 
Colombia Central/South America 
Region of the 
Americas Parkinson's disease Capture-recapture No Standardization 176.4 2004 
Cuba Central/South America 
Region of the 
Americas Parkinson's disease 
Population-Based  
(door-to-door) Local Standardized 135.0 1997 
Mexico Central/South America 
Region of the 
Americas Parkinson's disease - Local Standardized 170.0 2008 
Albania Europe European Region Parkinsonism Population-Based  (door-to-door) Local Standardized 800.0 2012 
Bulgaria Europe European Region Parkinson's disease Record-Based Global Standardized 141.1 2001 
Denmark Europe European Region Parkinson's disease Record-Based Local Standardized 183.3 1997 
England Europe European Region Parkinson's disease Record-Based Local Standardized 112.5 1961 
England Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 108.4 1982 
England Europe European Region Parkinson's disease Record-Based Global 70.9 1985 
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Standardized 
England Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 121.0 1992 
England Europe European Region Parkinson's disease Record-Based Global Standardized 73.5 1995 
England Europe European Region Parkinson's disease Record-Based Global Standardized 91.7 2000 
England Europe European Region Parkinson's disease Record-Based Local Standardized 142.0 2010 
Estonia Europe European Region Parkinson's disease Record-Based Global Standardized 111.3 2002 
France Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 320.0 1987 
France Europe European Region Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 101.0 1994 
France Europe European Region Parkinson's disease Record-Based Local Standardized 121.0 1994 
Germany Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 183.0 1987 
Germany Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 713.0 1992 
Italy Europe European Region Parkinson's disease Record-Based Global Standardized 61.4 1980 
Italy Europe European Region Parkinson's disease Record-Based Local Standardized 152.3 1986 
Italy Europe European Region Parkinson's disease Record-Based Global Standardized 100.4 1987 
Italy Europe European Region Parkinson's disease Record-Based Global Standardized 95.5 1991 
Italy Europe European Region Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 173.8 1992 
Italy Europe European Region Parkinsonism Record-Based Local Standardized 156.3 2001 
Italy Europe European Region Parkinson's disease Record-Based Global Standardized 89.7 2005 
Italy Europe European Region Parkinsonism Population-Based  (door-to-door) Local Standardized 323.4 2008 
Italy Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 215.6 2008 
Netherlands Europe European Region Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 216.0 1995 
Norway Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 102.4 1995 
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Portugal Europe European Region Parkinson's disease Record-Based Local Standardized 130.0 1992 
Russia Europe European Region Parkinson's disease Record-Based Local Standardized 76.5 2009 
Russia Europe European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 129.0 2011 
Scotland Europe European Region Parkinson's disease Record-Based Global Standardized 91.4 1986 
Spain Europe European Region Parkinson's disease Record-Based Local Standardized 161.5 1994 
Spain Europe European Region Parkinson's disease Record-Based Local Standardized 220.6 1995 
Spain Europe European Region Parkinson's disease Record-Based Global Standardized 93.8 1999 
Spain Europe European Region Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 117.6 2003 
Sweden Europe European Region Parkinson's disease Record-Based Global Standardized 76.0 1996 
Ukraine Europe European Region Parkinson's disease Record-Based Local Standardized 61.4 2013 
Egypt Middle East 
Eastern 
Mediterranean 
Region 
Parkinsonism Population-Based  (door-to-door) Local Standardized 316.5 2009 
Egypt Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based  (door-to-door) Local Standardized 213.1 2010 
Egypt Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based  (door-to-door) No Standardization 452.1 2012 
Egypt Middle East 
Eastern 
Mediterranean 
Region 
Parkinsonism Population-Based  (door-to-door) No Standardization 659.0 2012 
Iran Middle East 
Eastern 
Mediterranean 
Region 
Parkinsonism Population-Based  (door-to-door) 
Global 
Standardized 284.9 2012 
Iran Middle East 
Eastern 
Mediterranean 
Region 
Parkinsonism Population-Based  (door-to-door) Local Standardized 222.9 2012 
Iran Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 182.3 2012 
Iran Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based  (door-to-door) Local Standardized 142.7 2012 
Israel Middle East European Region Parkinson's disease Population-Based  No Standardization 240.0 2002 
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(door-to-door) 
Israel 
(Arab 
population) 
Middle East European Region Parkinson's disease Record-Based  (drug-tracer) Local Standardized 43.2 2010 
Jordan Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Record-Based No Standardization 58.8 2009 
Saudi 
Arabia Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based  (door-to-door) Local Standardized 27.0 1993 
Tunisia Middle East 
Eastern 
Mediterranean 
Region 
Parkinson's disease Population-Based (door-to-door) Local Standardized 216.0  
Turkey Middle East European Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 202.0 2011 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 51.3 1985 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 16.7 1991 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 112.2 1996 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 109.3 2003 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 112.2 2005 
China Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 176.9 2005 
India Asia South-East Asia Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 140.6 1993 
India Asia South-East Asia Region Parkinson's disease 
Population-Based  
(door-to-door) Local Standardized 76.0 2004 
Japan Asia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 68.3 1983 
Japan Asia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 57.9 1990 
Japan Asia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 68.2 1996 
Japan Asia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 61.4 1996 
Japan Asia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 35.8 2002 
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Korea Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) No Standardization 374.0 2007 
Singapore Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 61.9 2004 
Taiwan Asia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 113.1 2001 
Thailand Asia South-East Asia Region Parkinson's disease Record-Based No Standardization 424.6 2011 
Libya Africa 
Eastern 
Mediterranean 
Region 
Parkinson's disease Record-Based Local Standardized 60.0 2007 
Nigeria Africa African Region Parkinson's disease Population-Based  (door-to-door) Local Standardized 10.0 1987 
Tanzania Africa African Region Parkinson's disease Population-Based  (door-to-door) 
Global 
Standardized 40.0 2008 
Australia Australia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) 
Global 
Standardized 439.4 2005 
Australia Australia Western Pacific Region Parkinson's disease 
Population-Based  
(door-to-door) No Standardization 146.0 2006 
Australia Australia Western Pacific Region Parkinson's disease Record-Based 
Global 
Standardized 71.3 2007 
New 
Zealand Australia 
Western Pacific 
Region Parkinson's disease Record-Based 
Global 
Standardized 76.0 1992 
Findings from the current PhD project are highlighted in grey. 
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As it is shown in Table 2, different methods of standardization have been applied to adjust 
crude data on PD prevalence including either a global reference (i.e. WHO, USA or Europe 
standard reference populations), or national/regional references. Using a global hypothetical 
standard population has made it possible to fairly compare prevalence rate of PD between 
different countries with various national population pyramids with their own specific age and 
sex distribution [42].	  Among the globally standardized rates, the lowest and highest prevalence 
of PD has been reported from China (16.7/100,000) [35] and Australia (439.4/100,000) [43], 
respectively (Table 2). Throughout the studies that have reported only national standardized 
rates, PD prevalence ranges from 10.0/100,000 in all age groups in Nigeria [44] to 
713.0/100,000 among the population older than 65 years in Germany [45] (Table 2). 
1.2.4 Importance and knowledge gap 
Iran is the world's 17th most populous country with 78.4 million inhabitants [46], which is 
aging rapidly. This demographic shift has caused tremendous concerns for the future healthcare 
of Iranian population. According to the national census in Iran, the population aged 60 and 
older constituted 6.6% of the whole population (71 million) in 2006, which accounts for more 
than four million individuals [47]. Recently, the proportion of those with ≥60 yrs of age has 
increased 1% from 2006 to 2011 [48-49] and is estimated to reach 10.5% in 2025 and as high 
as 21.7% in 2050 [49-50]. This trend will lead to a rise in the incidence of neurodegenerative 
diseases including PD in near future, which implies a major health problem with its 
consequences to both healthcare system and society. There are a number of epidemiological 
studies from different developed countries as listed in Table 2 that provides useful knowledge 
and important information concerning the epidemiological and clinical aspects of PD, but little 
attention has been focused in Iran on the neuroepidemiology of PD. Moreover, data on the 
prevalence rate of PD in other countries could not be cited in other societies due to different 
ethnic groups and environments even from the neighboring countries. Therefore, it was 
necessary to perform a neuroepidemiologic study in Iranian population to achieve relevant data 
on PD prevalence. 
 
1.3 Nutritional status in parkinsonian patients 
1.3.1 Prevalence of malnutrition 
As a general aspect of daily life, nutritional status plays a crucial role in everyday’s well-being 
especially in patients suffering from a chronic condition such as PD [51-52]. Several symptoms 
potentially affect nutrition in PD patients including difficulty swallowing and chewing, 
drooling, dysphasia, motor problems in cutting and transporting the foods, constipation and 
even psychological disorders such as depression, which are associated with reduced food 
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intake and changes in dietary habits [53-56]. Dysphagia accompanies with difficulties in the 
intake of both solid and liquid foods in up to 50-70% of PD patients [57]. All these symptoms 
increase the risk of nutritional insufficiency in individuals with PD leading to a higher burden 
of disease, lower quality of life (QoL) and consequently increasing morbidity and mortality 
[55, 58]. One systematic review showed that the prevalence rate of malnutrition in PD varied 
between 0% and 24% in different studies, while 3–60% of them were at risk of malnutrition 
[59]. This wide range of estimations is largely attributed to different assessment methods 
applied for nutritional status in PD population [55, 59]. Two studies have estimated that 20-
23% of PD patients are at risk of malnutrition based on validated instruments such as the Mini 
Nutritional Assessment (MNA) [60-61]. Other investigations have mainly used anthropometric 
measurements such as body mass index (BMI) and weight showing different results.      
1.3.2 Risk factors of malnutrition   
On one hand, different motor and non-motor conditions, pharmacological treatment and side-
effects can influence nutritional status in PD patients [62-63]. On the other hand, malnutrition 
can also worsen the symptoms and different aspects of QoL such that improvement of 
nutritional status has been recently shown to improve QoL in PD patients [64]. Table 3 
summarizes the findings of investigations on the risk factors of nutritional insufficiency in PD 
patients. Several outcome measures have been evaluated including different anthropometric 
indices and various nutritional assessment tools in each of the previous studies. However, 
severity of motor symptoms [65-69], motor complications [70], psychiatric disorders [60, 67, 
69], disease duration [61], sex [66, 71] and age [66, 69], cognitive function [66-67], sleep 
disorder [60], gastrointestinal symptoms [60, 72] and medication [68-69] have been found to 
affect nutritional status in PD patients.        
1.3.3 Importance and knowledge gap 
Despite the hypothetical strong connection between PD and nutrition, prevalence of 
malnutrition and investigation of its determinants have been usually ignored. Few studies have 
estimated the magnitude of nutritional insufficiency in PD most of which have used weight, 
BMI and other anthropometric measurements as the main indicator. Lack of a matched control 
group from the same community as the patients is another methodological problem that affects 
the validity of interpretations [59]. Furthermore, even fewer studies have focused on a broader 
picture of nutritional status using validated instruments [i.e. MNA, Subjective Global 
Assessment (SGA)] other than just anthropometric indices in PD patients. Even though a 
couple of reports did use the MNA, still there is not enough evidence on the relationships 
between different features of PD, consisting of both motor and non-motor, and nutritional 
status as well as the counterfactual effects of malnutrition on QoL in PD patients.	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Table 3. Literature review on the list of determinant/risk factors for nutritional insufficiency in Parkinson’s disease patients 
 
Study Year Design Country Sample Size 
Disease Stage 
(H &  Y) Outcome Determinant Factors 
Durrieu et al 
[71] 1992 Cross-sectional France 65 
2.4 
(mean) 
Weight, CC 
Protein 
biomarkers 
Female sex 
Markus et al 
[70] 1993 Cross-sectional 
United 
Kingdom 95 
3 
(mean) 
Weight, BMI, 
MAC,	  skin-fold 
thicknesses 
Dyskinesia 
Beyer et al 
[65] 1995 
Longitudinal 
comparison 
with control 
group 
USA 51 2 (median) 
Weight, BMI, 
MAC, skin-fold 
thicknesses 
H & Y stage 
Lorefalt et al 
[66] 2004 
Longitudinal 
comparison 
with control 
group 
Sweden 26 - 
Weight, BMI, 
body fat mass, 
resting energy 
expenditure, 
energy intake 
Rigidity, Tremor, cognitive 
function, 	  female sex, age, 
low physical activity 
Uc et al [67] 2006 
Longitudinal 
comparison 
with control 
group 
USA 49 
2.1 
(mean at the 
middle of 
study) 
Weight 
H & Y stage, emergence of 
visual hallucinations, 
dementia 
Barichella et al 
[61] 2008 
Longitudinal 
comparison Italy 61 - 
MNA score, 
weight, BMI Disease duration 
Wang et al 
[60] 2010 Cross-sectional China 117 
2 
(median) MNA score 
Constipation, vomiting, loss 
of interest, inability to 
concentrate, depression, 
sleep quality, anxiety 
Barichella et al 
[68] 2013 Cross-sectional Italy 208 
2 
(median) 
MUST score, 
weight, BMI, 
MAC, skin-fold 
thicknesses 
Number of dysautonomia 
symptoms, H & Y stage,	  
levodopa dose 
Sheard et al 
[69, 72] 2013 Cross-sectional Australia 125 
2 
(median) 
SGA, weight, 
BMI, MAC, WC 
Loss of appetite, 
constipation, early satiety, 
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problems in swallowing,  
UPDRS-Part II, UPDRS-
Part III, weight-adjusted 
daily levodopa dosage,	  age 
at diagnosis, anxiety, 
depression, living alone 
Fereshtehnejad 
et al [73] 2014 Cross-sectional Iran 150 
2 
(median) 
MNA score, 
weight, BMI, 
MAC, CC, 
Total UPDRS, disease 
duration, female sex,  
weight-adjusted daily 
levodopa dosage, H & Y 
stage, anxiety, depression, 
fatigue 
H & Y: Hoehn and Yahr stage; MNA: mini nutritional assessment; SGA: subjective global assessment; BMI: body mass index; CC: calf 
circumference; MAC: mid-arm circumference; WC: waist circumference; MUST: malnutrition universal screening tool 
Findings from the current PhD project are highlighted in grey. 
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1.4 Quality of life in parkinsonian patients 
1.4.1 Determinants and correlates 
Health-related quality of life (HRQoL) is a major indicator for health outcome assessment in 
PD researches [74]. As a valid multi-dimensional index, HRQoL refers to the health aspects of 
daily life’s quality regarding physical health, emotional status and cognition [75]. With respect 
to the multisystem and chronic progressive nature of PD, it is of utmost importance to 
investigate the factors affecting HRQoL in people with PD. Patients with PD experience a wide 
range of motor and non-motor symptoms, each of which potentially affects different aspects of 
HRQoL including daily physical activity, as well as emotional and cognitive tasks. In spite of 
the growing number of studies on HRQoL in PD patients from different countries, it remains 
unclear which demographic and clinical factors are the key predictors of HRQoL [76]. While 
more attentions were conventionally paid to the cardinal motor features of PD, there is rapid 
increasing evidence showing the immense burden of NMSs on the lives of the people with PD 
[4]. It has been demonstrated from some previous studies that NMSs have a larger impact on 
patients’ HRQoL than motor symptoms [77-78]. Results from a recent systematic review 
concluded that depression, disease severity and disability, motor features such as gait 
impairments and complications of therapy were the major predictors of poor HRQoL in PD 
patients [76].  
1.4.2 Importance and knowledge gap 
Knowledge on the determinants of HRQoL in PD assists clinicians to target their examinations 
and treatment strategies in order to diminish the functional and emotional burden of PD [76]. 
Many studies have investigated the impact of different variables on HRQoL in PD patients 
including disease severity, motor and non-motor symptoms, nutritional status, demographic 
and socioeconomic characteristics [64, 73-74, 76, 79-83]. Thus far, a few of them have 
included the broad range of parkinsonian features all together, assess the interactions between 
different symptoms and the mediation pathways, and compare their independent role and 
strength of their effect on HRQoL. On the other hand, patients with PD show significant 
heterogeneity in their motor and non-motor features [84], which is a great obstacle in 
generalisability of the pattern and determinants of HRQoL for PD patients with different 
phenotypes.  
 
1.5 Heterogeneity in Parkinson’s disease 
It is now already known that no two PD patients are alike in clinical manifestations, response 
to treatment, overall prognosis, and many other aspects of PD. This heterogeneity makes PD an 
inappropriate disease to have a “one size fits all” caring approach [25, 85]. Diverse clinical 
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phenotypes of PD patients have recently highlighted the concept of heterogeneity and the need 
for identification of subtypes in PD. Defining different PD phenotypes and further clarification 
of their differences is crucial for a better understanding of underlying disease mechanisms and 
genetic features, prediction of disease course, and eventually perhaps more efficiently-designed 
personalized management strategies [19].  
1.5.1 Importance and knowledge gap 
The National Institute of Health has recently delineated subtype-identification as one of the top 
priorities in the field of PD clinical research [86]. While different research groups are now 
working on definition of distinct PD phenotypes, there is also a dearth of information about the 
heterogeneity in pattern and determinants of HRQoL between different PD subtypes.
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2 AIMS  
2.1 General aims 
Regarding the previously mentioned knowledge gap, the general goal of this project was to 
investigate neuroepidemiologic features of PD in Iran, focusing on screening and prevalence of 
parkinsonism, nutritional status, clinical and psychiatric features and quality of life. For this 
purpose, we also needed to validate several questionnaires and make a new screening 
instrument.   
 
2.2 Specific aims 
• Study I: This study had two objectives as follows: 
o to assess the validity and reliability of the Persian version of the short-form 
8-item Parkinson’s Disease Questionnaire (PDQ-8) 
o to compare psychometric properties of the short- versus long-form versions 
of the PDQ to evaluate HRQoL in PD patients 
• Study II: This study had two objectives as follows: 
o to devise and validate a sensitive and specific screening questionnaire for 
parkinsonism based on different symptoms of PD 
o to compare diagnostic value of our newly composed questionnaire with the 
previously developed screening instruments for parkinsonism 
• Study III: to estimate the prevalence rate of probable parkinsonism in the huge 
urban area of Tehran, Iran following a community-based door-to-door survey 
• Study IV: to estimate the prevalence of individuals with malnutrition or at risk of 
malnutrition in a community of Iranian PD patients and compare it with a matched 
control group using anthropometric measurements and MNA 
• Study V: This study had two objectives as follows: 
o to investigate the association between motor, psychiatric and fatigue 
features with nutritional status in PD patients using anthropometric 
measurements and MNA  
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o to evaluate the effects of nutritional insufficiency on different domains of 
HRQoL in people with PD 
• Study VI: This study had four objectives as follows: 
o to identify the factors that affect HRQoL in Iranian PD patients 
o to compare the independence and strength of their effects on HRQoL 
o to investigate the general pattern of HRQoL with the best hypothesized 
structural model 
o to explore the structural heterogeneity in the optimum model for HRQoL 
between different PD phenotypes    
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3 METHODS 
In the whole PhD project, data were collected through several settings as described here: 
3.1 Movement Disorder Clinic 
3.1.1 Setting and study population 
In study I, study II, study IV, study V and study VI, the entire or at least part of the data were 
collected from a referral Movement Disorders Clinic in Tehran, Iran. In this cross-sectional 
project a total number of 157 Iranian patients with IPD were consecutively recruited from this 
outpatient clinic during October 2011 and December 2012.  
3.1.2 Eligibility 
In study I, study IV, study V and study VI, patients were eligible for recruitment if they fulfilled 
the following inclusion criteria at the time of initial assessment: 
• Diagnosis of IPD based on the United Kingdom Brain Bank criteria [2] 
• Age ≥30 yrs 
Patients with any of the following characteristics were all excluded from the above-mentioned 
studies: 
• Cognitively unable to answer valid responses or moderate to severe dementia [mini-
mental state examination (MMSE)<24] [87] 
• Other types of parkinsonism such as multiple system atrophy (MSA), progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD) and vascular or drug-
induced Parkinsonism 
• Dystonia 
• Essential tremor 
In study II, patients with atypical parkinsonism (n=10), dystonia (n=14) or essential tremor 
(n=7) were also enrolled in the study to compare the diagnostic value of screening 
questionnaires for different discriminative purposes as described [88]. Of note, the same 
neurologist specialized in movement disorders evaluated all participants for eligibility. 
In study IV and in addition to the above-mentioned criteria, patients with other chronic 
comorbidities influencing nutritional state such as hypertension and diabetes mellitus and those 
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who were following special diets were also excluded since the main aim of this sub-study was 
to compare nutritional status between PD patients and healthy controls [55].   
3.1.3 Subgroups 
In study VI, IPD patients were divided into several subgroups regarding their onset-age, 
progression rate and dominant symptom as follows: 
• Onset-age: younger-onset (n=50, diagnostic age ≤50 yrs) versus older-onset (n=106, 
diagnostic age >50 yrs)    
• Progression: slow (n=95) versus rapid (n=40) based on the clustering solution 
recommended by Gasparoli et al [89]   
• Dominant symptom: tremor (n=76) versus non-tremor (n=75) based on the median 
value of the tremor motor score  
3.1.4 Data collection 
In the outpatient clinic, data collection was performed through face-to-face interviews with 
eligible patients and if necessary their caregivers by a trained group of medical interns and 
general physicians to fill in validated questionnaires and scales. As for diagnosis, all clinical 
examinations were done by the same movement disorders specialist for all patients. Medical 
records and documents were also used to collect some baseline information. All assessments 
were performed when the patients were in the “on” status. 
3.1.5 Variables  
In this phase of our project, the following variables and characteristics were recorded: 
• Demographic and baseline data:  
o age  
o sex  
o educational status  
o co-morbidities (type and total number)  
o duration of PD (time passed from diagnosis)  
o history of levodopa administration  
• Motor severity: 
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o Unified Parkinson's Disease Rating Scale (UPDRS) subscales I–IV, 1987 
version [90] 
o Hoehn and Yahr (H & Y) staging 
o Schwab and England activities of daily living (ADL) 
o motor impairment score [91]: score “A” as sum of UPDRS-Part III items on 
facial expression, tremor, rigidity, and bradykinesia (considered relatively 
dopamine-responsive) and score “B” as sum of UPDRS-Part III items 
concerning speech and axial impairment (considered relatively levodopa 
non-responsive) 
o dyskinesia score: sum of UPDRS-Part IV items 32-34 
o fluctuation score: sum of UPDRS-Part IV items 36-39  
• Motor subtypes: 
o postural-instability-gait-difficulty (PIGD) score [92]: sum of UPDRS-Part 
III items concerning rise, gait, and postural instability  
o FOSS score [92]: sum of UPDRS-Part II items on freezing, speech and 
swallowing 
o predominance of core manifestations: proportion of UPDRS-Part III ‘‘on’’ 
motor scores accounted for tremor (items 20–21), rigidity (item 22), 
bradykinesia (items 23–26 and 31), and gait (items 27–30) in percentage 
o asymmetry Index [93]: absolute differences in UPDRS between sides 
divided by the total UPDRS III (0 = “perfect symmetry”, 1 = “absolute 
asymmetry”) 
o axial/limb ratio: sum of UPDRS-Part III items 18, 19, 22 and 27-30 divided 
by sum of UPDRS-Part III items 20-26 
o presence of falls and freezing 
• Non-motor manifestations: 
o depression: evaluated by Hospital anxiety and depression scale (HADS) 
[94]  
o anxiety: evaluated by HADS [94]  
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o hallucinations/Illusions: evaluated using UPDRS-Part I, item 2 
o apathy: evaluated using UPDRS-Part I, item 4 
o fatigue: by means of the Fatigue Severity Scale (FSS) [95]   
o psychosocial functioning: evaluated by the scales for outcomes in 
Parkinson's disease-psychosocial questionnaire (SCOPA-PS) [96]  
• Nutritional status: using the Mini Nutritional Assessment (MNA) [97]  
• Anthropometric measurements:  
o weight 
o height 
o body mass index (BMI)  
o mid arm circumference 
o calf circumference 
• Health-related quality of life (HRQoL): evaluated by the Parkinson’s disease 
questionnaire (PDQ) [98] 
 
3.2 Control groups 
For two studies, control groups were enrolled to answer the underlying research questions. In 
study II, 110 healthy individuals without any history of neurological diseases who aged ≥40 yrs 
were recruited at the same period of time as for the cases. They were selected from an 
outpatient ophthalmology clinic and three senior medical students performed a complete 
neurological examination to confirm not having any symptomatic neurological deficit. After 
enrollment, the same baseline checklist and screening questionnaires were filled through face-
to-face interviews. In study II, the patients and controls were frequently matched by sex 
distribution and mean age [88].  
In study IV, another control group was selected consisting of 145 sex- and age-matched healthy 
individuals. For this purpose, the controls were randomly recruited from the medical staff and 
the patients’ relatives in Sina and Imam Khomeini hospitals in Tehran, Iran during the same 
period as for the cases in this sub-study (January 2012-September 2012). Regarding the main 
objective of study IV, the controls were selected from the same geographical region as the IPD 
patients in order to avoid the effect of cultural differences on nutritional habits. The similar 
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eligibility criteria were applied for the controls as for the case group except the patients 
exhibited PD symptoms. Therefore, similar to the case group, those participants under the age 
of 35 yrs, suffering from chronic conditions affecting their nutritional habits such as 
hypertension and diabetes, and those following special diets were excluded from the control 
group, too [55]. 
 
3.3 Community-based door-to-door study 
3.3.1 Setting and study population 
Data was collected from a different setting in study III. This community-based door-to-door 
study was performed in Tehran urban area, Iran during October 2011 and January 2012 as the 
prevalence date point. As the capital city of Iran, Tehran is the largest urban area in West Asia 
with a population of >8,300,000 inhabitants surpassing 14,000,000 in the wider metropolitan 
region [46] with 22 urban districts with heterogeneous population density according to the 
latest estimations (Figure 2). This study targeted adult population of Tehran urban area who 
aged ≥30 yrs at the time of assessment.  
 
 
 
 
 
 
 
 
 
 
Figure 2. Population density map of Tehran urban area in 22 districts (from: Atlas 
of Tehran Metropolis)     
 
3.3.2 Sampling method 
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As shown in Figure 2, Tehran urban area has 22 hierarchical districts regarding not only 
population density but also socioeconomic status. Therefore, it was crucial to perform 
sampling in a way to cover all regions with a representative selected population. For This 
reason, we used a probability multistage sampling method covering all 22 urban districts of 
Tehran in study III. Each district was considered as one sampling stratum where each of them 
consisted of several blocks and households as the clusters. Throughout Tehran area, there is a 
network of “Health Centers” consisting of 374 subunits covering all districts, which are 
organized by the health deputy of Tehran municipality. Each of the “Health Centers” is 
responsible for a determined number of residing blocks and households that are coded by 
unique numbers. Following stratification, we used cluster sampling to randomly select the 
needed number of households within the coverage zone of each “Health Centre” to fulfill the 
calculated proportional sample size for each subunit in every district. This procedure was 
performed for each district and subunit resulting in representative selected households.  
3.3.3 Data collection 
In study III, data collection was performed through face-to-face interviews with the inhabitants 
of selected households. In September 2011, a one-day workshop was held to train the 
surveyors who were mostly healthcare workers employed by the "Health Centers" of each 
district. Each of the surveyors was responsible for a determined number of households within 
their affiliated subunit and district. All members of each selected household were asked to 
participate in the survey if they aged ≥30 yrs and agreed to contribute after necessary 
information about the survey and study aims was given. After agreement, study checklist was 
filled through face-to-face interview by the surveyor, which consisted of three main sections 
including demographic information (i.e. age, sex, educational level, marriage and working 
status), comorbidity profile and screening questions. In study III, we used the screening 
questionnaire for parkinsonism validated in study II [88]. In overall 20,621 individuals 
answered study checklist including baseline variables and screening questionnaire. 
Nevertheless, information from 19,500 persons were entered in the final analysis regarding 
missing values and data cleaning, which showed 94.6% rate of valid participation. 
 
3.4 Instruments, questionnaires and measurements 
3.4.1 Screening questionnaire 
To make the new screening tool in study II, we evaluated all of the symptoms previously 
included in questionnaires for screening of PD. Following thorough literature review, the 
questions that require no physical examination and were the best representative for each PD 
symptom were selected. This comprehensive list was actually constructed by combining the 
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items from previously validated questionnaires used for screening of PD including the 
screening instrument of the Sicilian neuro-epidemiology study (SNES) [99], the Baylor Health 
Screening Questionnaire (BHSQ) [100], telephone questionnaire for Parkinson’s disease [101], 
original and modified WHO screening instruments to measure the prevalence of neurological 
disability in resource-poor settings [102-103] and the questionnaires either developed or 
modified by Tanner [104], Daurate [105], Chan [106], Setthawatcharawanich [107] and 
Sevillano [108]. A bilingual person translated all of these questions into Persian language and 
wording was trans-culturally approved by the experts for face validity. Of note, some general 
questions on non-PD specific neurologic symptoms from the SNES questionnaire [99] were 
kept in the merged instrument to check the validity of the answers from the patients. The new 
comprehensive preliminary questionnaire consisted of 25 unique items (Table 9) on different 
neurological symptoms. Appendix 1 shows all questions that were used in this screening 
instrument and the ones that were finally selected. In order to prevent information bias, 
surveyors thoroughly explained technical terms and symptoms for all subjects including those 
controls who might not be familiar with the symptoms and/or have lower level of education. 
3.4.2 Fatigue severity scale (FSS) 
The FSS is an easy-administered tool to evaluate fatigue in a variety of medical and neurologic 
disorders. The scale assesses relationship between fatigue intensity and functional disability. It 
consists of nine questions with a seven-point Likert scale from 1 to 7, stating “strong 
disagreement” to “strong agreement”. Each patient is asked to rate the level of fatigue during 
the previous week and a total average score ranging from 0 to 7 where higher scores 
correspond to more severe fatigue is calculated for each patient [95]. The FSS was previously 
translated into Persian language and has been found to be valid and reliable in patients with 
multiple sclerosis [109]. During the validation phase of this project, we evaluated psychometric 
properties of the Persian-translated version of the FSS in Iranian patients with IPD [110]. 
3.4.3 Hospital anxiety and depression scale (HADS) 
The HADS is a self-assessment screening tool that was designed to determine levels of anxiety 
and depression in a non-psychiatric population attending medical clinics. It has 14 questions in 
two sections: seven questions are related to depression and the other seven focus on anxiety. 
Each question is scored from 0-3, where 0 = “not at all”, and 3 = “very often indeed”, 
therefore, each section is worth 0–21 points by adding up the answers for all items that 
provides separate scores for either depression or anxiety where in both sub-scales, a higher 
score shows more severe condition [94]. The Persian-version of the HADS questionnaire has 
been previously shown to have a Cronbach’s alpha coefficient of 0.78 for anxiety and 0.86 for 
depression [111].  
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3.4.4 Scales for outcomes in Parkinson's disease-psychosocial questionnaire 
(SCOPA-PS) 
The SCOPA-PS questionnaire is a self-administered 11-item scale assessing severity of 
psychosocial functioning during the last month. Items are scored with a four-point Likert scale 
ranging from 0 = “not at all” to 3 = “very much”. By adding up the scores of the individual 
items, the sum score is calculated, which is then transformed into percentage values. This 
summary index ranges from 0 to 100% such that the higher scores indicate worse psychosocial 
functioning [96]. During the validation phase of our project, three native Persian speakers 
fluent in English translated the SCOPA-PS into Persian. Later on an English-native fluent in 
Persian who had neither access to the original version of the questionnaire nor involved in the 
study back translated the SCOPA-PS into English. Wording modifications were performed 
following the comparison of the back-translated versus the original version of the SCOPA-PS. 
Finally, the confirmed joint version was named “SCOPA-PS, Persian version” and its 
psychometric properties were examined prior to be applied in the main sub-studies [112]. 
3.4.5 Anthropometric measurements  
Anthropometric measurements consisting of mid arm circumference (MAC), calf 
circumference (CC), weight and height were performed by trained medical staff for all 
participants in study IV, study V and study VI. Calibrated floor scales were used to measure 
body weight between 3 p.m. and 5 p.m. while the subjects wore light clothing with no shoes or 
coats. For all patients, standing height was measured by means of a stadiometer at the head 
level, with the subject’s bare feet close together, standing erect and looking straight ahead. No 
height adjustment was needed since there was no case of considerable stooped posture. Body 
mass index was calculated as body weight (kg) divided by the square of height (m2). For MAC 
measurement, the mid-point between the acromial surface of scapula and the olecranon process 
of elbow was marked by the examiner on the back of the arm, while the subjects were holding 
their forearm in a horizontal position with their palm up. Afterwards, a flexible inextensible 
tape was circled around the maximum girth of the proximal part of forearm to record MAC 
while the subject’s arm was hanging down freely along their trunk at their sides. In order to 
gauge CC, a flexible tape was circled around the maximal circumference between the ankle 
and the knee in standing position [50].  
3.4.6 Mini-nutritional assessment (MNA) 
As a combined screening and assessment tool, MNA is a rapid instrument to identify risk of 
malnutrition. The questionnaire is composed of 18 brief items divided into two sections: 6 
screening questions in section I (14 points) and 12 assessment questions in section II (16 
points). The items include BMI, weight loss, MAC, CC, appetite, medication, general and 
cognitive health, dietary matters, autonomy of feeding, self-perception of health and nutrition 
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and subjective judgment of malnutrition. Total score of the MNA ranges between 0 and 30 
where a score of <17 indicated “malnutrition”, scores of 17–23.5 points signified cases of 
being “at risk for malnutrition”, and the scores ≥24 points indicates “normal nutritional status” 
[97]. In our project, we have used the Persian-translated version of MNA provided by Nestlé 
Nutrition Institute. Validity and reliability of this tool was checked during the validation phase 
of our project [113].  
3.4.7 Parkinson’s disease questionnaire (PDQ) 
The PDQ is the most common disease-specific measure to assess health-related quality of life 
(HRQoL) in PD patients. In the long format of the questionnaire (PDQ-39), 39 items assess 
eight aspects of HRQoL in PD consisting of: mobility (10 questions), activities of daily living 
(ADL) (6 questions), emotional well-being (6 questions), stigma (4 questions), social support 
(3 questions), cognitions (4 questions), communication (3 questions) and bodily discomfort (3 
questions). The questions are coded in a Likert-scale from 0 to 4, where 0 = “never”, 1 = 
“occasionally”, 2 = “sometimes”, 3 = “often” and 4 = “always”. A score ranging from 0 to 
100% is calculated for each domain. The average score of all domains provides a single figure 
from 0 to 100%, called PD summary index (PDSI) in which zero indicates the best level of 
HRQoL and 100% represents the worst condition [98]. The short version of the PDQ (PDQ-8) 
has only eight questions consisting of one single item representing each of the HRQoL 
domains. In this project, we used the Persian-translated version of the PDQ-39 questionnaire, 
which has been previously demonstrated to have high reliability with a Cronbach’s alpha 
coefficient of 0.93 for the total questionnaire [114]. Moreover, we extensively assessed 
psychometric properties of the Persian version of the PDQ-8 in study I [115]. 
3.4.8 Unified Parkinson's disease rating scale (UPDRS) 
The UPDRS is an efficient tool, which is most commonly used in clinical studies of PD [116]. 
The scale covers different aspects of the disease such as NMS (part I), ADL (part II), motor 
examination (part III) and treatment complications (part IV). In our project, we have used all 
the subscales I – IV, 1987 version consisting of 42 items with a maximum score of 147 that 
indicates worst disability [90, 117]. Two other scales have been supplanted by the UPDRS 
namely Hoehn and Yahr Stage and Schwab and England ADL, both of which have been used 
in our project. The Hoehn and Yahr stage is a widely accepted staging system to describe 
progression of PD symptoms, which assesses daily activity limitations and the disease severity 
based on clinical findings and functional disability. It is expressed as a number on a scale of 0 
through 5, where a higher stage represents greater levels of functional disability. In stage 0 
there are no visible symptoms of PD, and in stage 5 symptoms are present on both sides of the 
body, indicating patients who are not able to walk [118]. The Schwab and England ADL is a  
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scale that estimates the ability to perform daily activities in terms of speed and independence in 
PD patients. A completely independent individual gets 100% score and a complete dependent 
individual, as seen in bed-ridden patients, gets a score of 0%. Therefore as the score increases, 
the level of independence is higher indicating a lower level of disability [119]. Table 4 
summarizes the main characteristics of the scales and questionnaires that have been used in our 
project. 
Table 4. Number of items, domains, range and direction of the scores for the scales and 
questionnaires used in this project   
 
Questionnaire/Scale Number of Items Domains/Sections 
Range 
of 
Score 
Direction of 
Score 
Unified Parkinson's 
Disease Rating Scale  
(UPDRS) 
42 
Part I (Mentation) (4 items) 
Part II (ADL) (13 items) 
Part III (Motor examination) 
(14 items) 
Part IV (Complications)  
(11 items) 
0-147 Higher score	  ≈   Higher severity 
Hospital Anxiety and 
Depression Score  
(HADS) 
14 Depression (7 items) Anxiety (7 items) 0-21 
Higher score≈ 
More severe 
depression/anxiety 
Fatigue Severity 
Scale (FSS) 9 Fatigue 0-7 
Higher score≈ 
More severe 
fatigue 
Scales for Outcomes 
in Parkinson's 
Disease-
psychosocial 
Questionnaire  
(SCOPA-PS) 
11 Psychosocial functioning 0-100% 
Higher score≈ 
Worse 
psychosocial 
functioning  
Mini Nutritional 
Assessment  
(MNA) 
18 Screening (6 items) Assessment (12 items) 0-30 
Lower score≈ 
Worse nutritional 
status 
Parkinson’s Disease 
Questionnaire-39 
items  
(PDQ-39) 
39 
Mobility (10 items)  
ADL (6 items) 
Emotional well-being  
(6 items)  
Stigma (4 items) 
Social support  (3 items) 
Cognitions (4 items) 
Communication (3 items) 
Bodily discomfort (3 items) 
0-100% 
Higher score≈ 
Poorer quality of 
life 
Parkinson’s Disease 
Questionnaire-8 
items  
(PDQ-8) 
8 Health-related quality of life  (HRQoL) 0-100% 
Higher score≈ 
Poorer quality of 
life 
ADL: activities of daily living 
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3.5 Statistical methods 
3.5.1 Sample size calculations 
Regarding the prevalence rate of 257/100,000 for PD patients that was estimated in a door-to-
door survey in Caucasians[120], and the effect size of 7/100,000 with the assumption of 0.05 
for type I (α) error in the estimation, total needed sample size was calculated as 16,000 
individuals for study III, using the following formula (where P represents the estimated 
prevalence rate and d shows the effect size of the estimation): 
d
Z PPN 2
2
)1( −×
= α  
3.5.2 Description 
Data were described and analyzed using IBM SPSS Statistics for Windows, version 22.0 
(Armonk, NY: IBM Corp.). For description of categorical variables frequency percentage was 
used. For continuous variables, mean and standard deviation (SD) were reported if the 
normality of distribution was shown by the Kolmogorov-Smirnov test. Otherwise, median and 
interquartile range (IQR) was used to describe skewed numeric variables. In validation studies, 
minimum, maximum and coefficient of variation (CV) were also reported for each of the items 
of the assessed questionnaires. In order to guarantee the acceptability of a scale, floor and 
ceiling effects were calculated, which were considered acceptable if less than 15% [121].  
3.5.3 Standardized prevalence rates 
To calculate the 95% confidence intervals (CIs) for prevalence rates of parkinsonism in study 
III, standard error (SE) of estimation was calculated using following formula (“P” is the point 
prevalence rate and “N” is the total sample size): 
SE = P(1−P)N 	  
Data on the age and sex distribution of the entire Tehran population based on the latest 
accessible national census [46] was used to adjust crude prevalence rates. Furthermore, we 
used “WHO Standard Population” as a unique standard age- and sex-specific distribution of a 
hypothetical population [122] to readjust the prevalence rates with an international reference to 
be able to compare the prevalence rates of our study with other countries. 	  
3.5.4 Reliability and validity 
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In validation studies, reliability and internal consistency of the questionnaires were examined 
using Spearman correlation test where the mean score of each item was correlated with the 
total score of each scale. Furthermore, Cronbach’s alpha intraclass coefficient and its 95% 
confidence interval (CI) were also calculated for the entire questionnaire, within each domain 
if applicable and different subgroups of PD patients regarding age-group, sex, level of 
education and disease severity. Criterion validity of each scale was also assessed by means of 
Spearman correlation coefficient between the total score of the questionnaires and the baseline 
characteristics as well as PD-related variables. 
3.5.5 Factor analysis 
In study I, the unidimensionality of the PDQ-8 questionnaire was checked by confirmatory 
principal factor analysis. An Eigen value of greater than 1 was considered as the best-fitted 
structure for the scale (Kaiser rule), however, the tendency to overextract the number of factors 
was also taken into account [123]. The Cattell scree plot was also drawn where the components 
were shown as the X-axis and the corresponding Eigen values as the Y-axis (Figure 3).     
3.5.6 Diagnostic values 
In study II, sensitivity and specificity were calculated based on the numbers of true positive, 
true negative, false positive and false negative answers for each single item of the screening 
instrument and the entire scale as well. Youden’s index (ranges between 0-1) was calculated 
as: (sensitivity + specificity)-1 [124], where a higher score indicated better diagnostic value. 
We applied the concept of clinical utility index (CUI) in order to select the optimal items for 
development of the new screening tool in study II. The corresponding CUI for each single 
screening item was calculated using an Excel calculator (http://www.psycho-
oncology.info/cui.html). According to Mitchell et al [125], positive CUI is defined as: 
sensitivity × positive predictive value (PPV), which represents the ability of the scale for ruling 
in the patients (case-finding). Negative CUI is calculated as: specificity × negative predictive 
value (NPV), which shows how well the instrument or item is for ruling out the patients 
(screening). Both positive and negative CUIs range between 0 to 1 and a value of ≥0.81, ≥0.64, 
≥0.49, <0.49 and <0.36 shows excellent, good, fair, poor and very poor utility, respectively 
[126]. In study II, the items with at least good negative utility (CUI≥0.64) for screening of the 
parkinsonism from healthy condition were included in the new screening tool. 
3.5.7 Receiver operating characteristics (ROC) curve analysis 
In order to evaluate the discriminant ability of different screening questionnaires, ROC analysis 
was performed in study II to calculate the area under curve (AUC) and its 95% CI for each 
scale and compare their diagnostic accuracy to screen patients with parkinsonism. The optimal 
cut-off value of each screening scale was determined based on the CUI and Youden’s index of 
33	   Neuroepidemiology	  of	  Parkinson’s	  disease	  in	  Iran	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
the recommended points through ROC analysis. In addition, we also implied ROC analysis in 
study I to compare the value of the total PDQ-8 and PDQ-39 scores to differentiate several PD-
related conditions. Based on the median values in this study, UPDRS (total, part I and part III) 
scores, Hoehn & Yahr scale and Schwab & England ADL score were dichotomized into 
dummy variables as the predicted conditions in each of the ROC analysis. Then, comparisons 
were performed regarding the AUC of PDQ-8 and PDQ-39 scores and their corresponding 
95% CI. 
3.5.8 Univariate analyses  
Chi square and Fisher’s exact tests were used to compare relative frequency of categorical 
variables between study subgroups wherever appropriate. For between-group comparisons of 
continuous variables, independent samples t test was applied if the assumption of normal 
distribution was met. In case of skewed variables, the non-parametric Mann-Whitney u test 
was used. In all analytical procedures, a two-sided p-value <0.05 was considered as the 
statistical threshold to reject the beyond null hypothesis. Univariate associations between 
continuous variables were assessed using either Spearman or Pearson correlation tests.  
3.5.9 Multivariate analysis 
Multivariate linear and/or binary logistic regression models were performed for numeric or 
categorical outcome variables/conditions, respectively. For this purpose, significant univariate 
demographic variables were used for statistical adjustments, and the best representative 
variables from motor severity, motor subtypes and non-motor assessments were used as the 
main independent predictors/determinants. In all regression procedures, either beta coefficient 
or odds’ ratio (OR) and their 95% CI were reported to present the strength of each association. 
We avoided including correlated indicators of one single entity. Tolerance index representing 
the proportion of variance for each independent variable that are not explained by other 
independent variables in the model, were calculated and were considered acceptable if  >0.4. 
Conventionally, the variance inflation factor (VIF) (1/tolerance) was also reported and aimed 
to be <2.5 to prevent collinearity in the models. If the collinearity occurred, the variable with 
higher tolerance and larger standardized coefficient was kept and the other collinear variable 
was deleted from the regression model. In study IV, the two-way analysis of variance 
(ANOVA) was performed to adjust for the probable confounding effect of level of education 
on the main between-group comparisons. 
3.5.10 Missing data imputation 
Prior to perform structural equation modeling and cluster analyses and in order to avoid case-
wise deletion and decreased statistical power, missing values of the database used for study VI 
were imputed. Only variables with at least 70% valid data and classified as “missing at 
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random” according to our judgment were eligible for imputation. Multiple imputation was 
carried out using independent regression equations where five different values were predicted 
for each single missing data. This methodology has been shown to have less biased parameter 
estimates than removing patients with missing values or other imputation methods such as the 
mean replacement [127]. As a result, a total of 95 single missing values were imputed 
accounting for 0.25% of the whole datasheet. 
3.5.11 Cluster analysis 
Two-step cluster analysis was applied to implement the clustering solution recommended by 
Gasparoli et al [89]. This clustering solution is based on current UPDRS-part II and part-III 
scores, dyskinesia and motor fluctuations to divide PD patients into two clinical phenotypes 
namely “slow-progression” and “rapid-progression”, which we used in study VI.   
3.5.12 Structural equation modeling (SEM) 
This statistical method was applied in study VI to create a structural model for HRQoL in PD 
using the AMOS 22.0 module of the SPSS	  software version 22.0 (IBM., Chicago, IL, USA). 
Appropriate observed variables were firstly included in the SEM based on a hypothetical 
model and literature review. Three latent variables were placed in the SEM representing global 
motor, non-motor and HRQoL components. Afterwards, observed variables with non-
significant estimates in the regression table were excluded. In the next step, recommended 
modifications to improve the structural model were added resulting in at least 20-unit decrease 
in the Chi square value of the whole model. In borderline cases when the difference between 
two models (with vs. without a specific modification) was small, the model with lower 
Bayesian information criterion (BIC) was selected. From each finalized SEM, the standardized 
regression weight (SRW) for each included component was reported. Fitness of each SEM was 
assessed using the absolute fit indices consisting of Normed Fit Index (NFI), Comparative Fit 
Index (CFI), Tucker-Lewis Index (TLI) and Root Mean Square Error of Approximation 
(RMSEA). An NFI, CFI and TLI value between 0.06 and 0.08 and RMSEA <0.08 indicate an 
acceptable model fit [128]. 
 
3.6 Ethical considerations 
The study protocol for the whole PhD project was approved by the ethics committee of the 
neurology department at Firoozgar Clinical Research Development Center (FCRDC) 
(affiliated to Iran University of Medical Sciences) in Tehran, Iran. The application was 
accepted and issued with the number MT/140 on 25 June 2011. All procedures in research 
studies of this project were conducted in accordance with the ethical standards of the latest 
version of the Helsinki Declaration. Each participant was informed about the aims and 
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objectives of each study before participation and the completion of the questionnaire was 
voluntary in all studies. Furthermore, the identity of research participants was protected, since 
the data files were anonymous and all names were omitted. The FCRDC ethical committee was 
responsible for confirming that all collected data was kept confidential and no third-party had 
access to the collected personal health data. 
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4 RESULTS 
4.1 Demography and baseline characteristics 
4.1.1 Parkinson’s disease patients 
All demography, baseline, clinical and assessment characteristics of 157 IPD patients recruited 
from the Movement Disorders Clinic are summarized in Table 5. At the time of enrollments, 
the average age of participants was 61.4 (SD=11.2) yrs and 49 (31.2%) patients were female. 
In study I, study II, study IV, study V and study VI, either in part or entirely, we have used data 
from this population, which were mainly in the mild to moderate stages of PD with a mean 
UPDRS score of 32.2 (SD=18.1) and mean disease duration of 6.8 (SD=5.2) yrs.   
Table 5. Demography, baseline, clinical and assessment characteristics of the Parkinson’s 
disease patients from the Movement Disorders Clinic (n=157) 
 
Characteristics Value 
Ø Demography and General Information 
Age-year (mean ± SD) 
Current 
At disease onset 
 
61.4 ± 11.2 
54.7 ± 11.9 
Gender NO (%) 
Female 
Male 
 
49 (31.2) 
108 (68.8) 
Level of Education NO (%) 
Illiterate 
Primary and/ or secondary 
High school/diploma 
College and/ or university 
 
17 (11.0) 
37 (23.9) 
43 (27.7) 
58 (37.4) 
Comorbidities NO (%) 
Hypertension 
Ischemic heart disease 
Osteoarthritis 
Diabetes 
Stroke/Transient ischemic attack 
Chronic obstructive pulmonary disease 
Total score  (mean ± SD) 
 
28 (18.1) 
24 (15.7) 
19 (12.4) 
20 (13.1) 
1 (0.7) 
1 (0.7) 
0.6 ± 1.0 
Duration of Parkinson’s Disease-year (mean ± SD) 6.8 ± 5.2 
Levodopa Dose-mg (mean ± SD) 
Cumulative daily dose 
Weight-adjusted daily dose 
 
864.7 ± 447.8 
12.6 ± 7.2 
Ø Assessments 
UPDRS Score (mean ± SD) 
Part I- Mental 
 
2.1 ± 2.4 
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4.1.2 Community-based population 
In study III, 12,907 (66.2%) women and 6,593 (33.8%) men with the mean age of 56.5 
(SD=10.2) yrs ranging between 30 and 95 yrs participated in the community-based door-to-
door survey. Majority of the study population (81.8%, n=15,147) were married and less than a 
quarter (22.4%, n=3,989) were retired. Hypertension (29.9%, n=5,838), osteoarthritis (18.0%, 
n=3,519) and diabetes (18.0%, n=3,516) were recorded as the commonest morbidities, 
respectively. 
 
4.2 Validations studies  
Part II- ADL 
Part III- Motor 
Part IV- Complications 
Dyskinesia 
Fluctuations 
Total score 
11.7 ± 7.4 
15.5 ± 9.2 
3.4 ± 2.8 
0.9 ± 1.7 
1.7 ± 1.3 
32.2 ± 18.1 
Hoehn and Yahr Stage median (IQR) 2 (1.5) 
Schwab and England Activities of Daily Living Score-(%) 
(mean ± SD) 80.5 ± 18.0 
Anxiety Score (HADS) (mean ± SD) 6.8 ± 5.1 
Depression Score (HADS) (mean ± SD) 5.1 ± 4.4 
Fatigue Score (FSS) (mean ± SD) 4.5 ± 1.9 
Nutritional Status (MNA) (mean ± SD) 
Screening score 
Assessment score 
Total score 
 
12.7 ± 2.0 
12.6 ± 1.9 
25.2 ± 3.3 
Psychosocial Functioning Score (SCOPA-PS)-(%) 
(mean ± SD) 25.9 ± 22.3 
Quality of Life (PDQ-39) (mean ± SD) 
Dimension I-Mobility 
Dimension II-Activity of daily living (ADL) 
Dimension III-Emotional well-being 
Dimension IV-Stigma 
Dimension V-Social support 
Dimension VI-Cognitions 
Dimension VII-Communication 
Dimension VIII-Bodily Discomfort 
 
28.2 ± 26.4 
26.4 ± 25.6 
28.4 ± 23.6 
21.9 ± 25.2 
11.5 ± 20.3 
17.9 ± 20.1 
15.1 ± 19.5 
22.1 ± 23.0 
Parkinson’s disease summary index (PDSI)  
(mean ± SD) 21.2 ± 15.4 
SD: standard deviation; IQR: interquartile range 
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In the validation phase of the project, five questionnaires were evaluated consisting of FSS, 
SCOPA, MNA, PDQ-39 and PDQ-8. For this purpose, we performed four validation studies, 
which are briefly described afterwards. Validity and reliability findings of each of these studies 
are listed in Table 6.    
4.2.1 Fatigue severity scale (FSS) 
Using data on 90 patients with IPD recruited from the Movement Disorder Clinic, the internal 
consistency coefficient of the Persian-translated FSS was shown to be larger than 0.8 for all of 
the items and the total Cronbach’s alpha was 0.96 (95% CI: 0.95-0.97) [110]. As shown in 
Table 7, the FSS had high Cronbach’s alpha coefficient (≥0.93) within all subgroups of PD 
patients regarding age groups, sex, educational level and disease severity assessed by the 
Hoehn & Yahr stage. The total score of the FSS was significantly valid to discriminate patients 
with more severe disability (Hoehn & Yahr stage>2) from those with less severity (Hoehn & 
Yahr stage≤2) [AUC=0.81 (95% CI: 0.72-0.90)] [110].     
Table 6. Validity and reliability of the Persian-translated versions of the questionnaires used 
in this project 
 
Questionnaire Sample Size 
Reliability Validity 
Internal 
Consistency 
Spearman r 
(Range) 
Internal 
Consistency 
Cronbach’s α 
(95% CI) 
Correlation 
Coefficient 
UPDRS-total 
score 
(Pearson r) 
Correlation 
Coefficient 
Hoehn & 
Yahr 
(Pearson r) 
Fatigue Severity Scale 
(FSS) 90 0.76-0.92 
0.96  
(0.95-0.97) 0.55 0.48 
Scales for Outcomes in 
Parkinson's Disease-
psychosocial 
Questionnaire  
(SCOPA-PS) 
110 0.55-0.77 0.87  (0.83-0.90) 0.55 0.34 
Mini Nutritional 
Assessment  
(MNA) 
143 0.03*-0.53 0.70  (0.62-0.77) -0.63 -0.43 
Parkinson’s Disease 
Questionnaire-39 items  
(PDQ-39) 
114 0.57-0.87 0.94  (0.92-0.95) 0.64 0.44 
Parkinson’s Disease 
Questionnaire-8 items  
(PDQ-8) 
114 0.46-0.70 0.74  (0.66-0.81) 0.59 0.38 
CI: confidence interval 
All coefficients are statistically significant (p-value<0.05) except for Spearman internal consistency of 
two items in the MNA questionnaire (*). 
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4.2.2 Scales for outcomes in Parkinson's disease-psychosocial questionnaire 
(SCOPA-PS) 
SCOPA-PS was validated in 110 Iranian patients with IPD. Independent native speakers 
approved content validity through translation and back-translation method. The overall 
Cronbach’s alpha coefficient for reliability was 0.87 (95% CI: 0.83-0.90). In item-specific 
analysis, the highest and lowest internal consistency was observed in item-7 on “asking for 
help” (r=0.765) and item-5 on “sexual problems” (r=0.553), respectively [112]. Table 8 shows 
the results for the linear regression model to determine the factors independently affect total 
score of the SCOPA-PS questionnaire in recruited IPD patients. After exclusion of the non-
significant variables, a regression model was achieved (R2=0.703, p<0.001) including HADS 
anxiety (B=0.71, p=0.020) and depression (B=1.53, p<0.001) scores, and the cognition 
(B=0.17, p=0.047), stigma (B=0.21, p<0.001) and mobility (B=0.21, p=0.003) domains of the 
PDQ-39 questionnaire.     
4.2.3 Mini-nutritional assessment (MNA) 
Another validation study was performed on 143 IPD patients to evaluate validity and reliability 
of the Persian-version of the MNA. The Cronbach’s alpha coefficient for the entire MNA was 
calculated as 0.70 (95% CI: 0.62-0.77). Nevertheless, reliability coefficient was significantly 
higher among the younger patients (age <65 yrs) [0.75 (95% CI: 0.67-0.82) vs. 0.55 (95 CI%: 
0.37-0.71), p<0.05]. The total score of the MNA significantly correlated with weight (r=0.427, 
p<0.001), MAC (r=0.268, p=0.001) and CC (r=0.285, p=0.001) and could discriminate IPD 
patients with BMI ≥24 kg/m2 (AUC=0.71, p<0.001). The cut-off value of 26 for the total MNA  
Table 7. Reliability (Cronbach’s α) of the Parkinson Disease Questionnaire (PDQ-8) and 
Fatigue Severity Scale (FSS) questionnaires within various subgroups of Iranian Parkinson’s 
disease patients 
 
Subgroups Cronbach’s α Coefficient PDQ-8 FSS 
Age Group <65 yr 0.65 (0.51-0.76) 0.97 (0.95-0.98) ≥65 yr 0.84 (0.76-0.90) 0.95 (0.92-0.97) 
Gender Female 0.69 (0.47-0.85) 0.93 (0.88-0.96) Male 0.76 (0.67-0.83) 0.97 (0.95-0.98) 
Educational Level 
Illiterate/Primary/ 
Secondary school 0.77 (0.68-0.84) 0.94 (0.92-0.96) 
College/University 0.58 (0.35-0.74) 0.98 (0.97-0.99) 
Hoehn & Yahr 
Stage 
≤2 0.71 (0.60-0.80) 0.95 (0.93-0.97) 
>2 0.75 (0.61-0.86) 0.94 (0.90-0.97) 
All coefficients are statistically significant (p-value<0.001) 
RESULTS	   40	  
	  
score had 58% sensitivity and 82% specificity for this discrimination [113]. 
 
4.2.4 Parkinson’s disease questionnaire (PDQ) 
In study I, psychometric properties of the Persian-translated version of the PDQ-8 
questionnaire were assessed in 114 IPD patients from our Movement Disorders Clinic. Figure 
3 shows the Scree plot for PDQ-8 questionnaire demonstrating one-factor structure as the best 
fitted model, which explained 37.31% of the variance of the PDQ-8 scores (Eigen value=2.98). 
 
 
 
 
 
 
 
Table 8. Multivariate linear regression model of the independent scales/variables relating to 
the total score of the SCOPA-PS questionnaire in Iranian Parkinson’s disease patients 
(n=110) (R2=0.703, p<0.001)  
 
Scales/ 
Variables 
Unstandardized 
Coefficients 
Standardized 
Coefficients t p-value 
95% CI for B 
B SEM Beta Lower Bound 
Upper 
Bound 
HADS 
Depression 1.534 0.408 0.305 3.76 <0.001* 0.723 2.345 
PDQ-39 
Cognition 0.173 0.086 0.161 2.02 0.047* 0.002 0.344 
PDQ-39 
Stigma 0.208 0.056 0.243 3.75 <0.001* 0.098 0.319 
PDQ-39 
Mobility 0.215 0.070 0.253 3.08 0.003* 0.076 0.355 
HADS 
Anxiety 0.711 0.301 0.180 2.36 0.020* 0.113 1.310 
Constant -1.501 2.029 - -0.74 0.461 -5.536 2.533 
SEM: standard error of mean, CI: confidence interval   
*	  Statistically significant (p-value<0.05)	  
Figure 3. Scree plot to evaluate the number 
of components that best fit the variances of 
the answers to the PDQ-8 questionnaire in 
Iranian Parkinson disease patients 
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Both PDQ-39 [Cronbach’s alpha=0.94 (95% CI: 0.92-0.95)] and PDQ-8 [Cronbach’s 
alpha=0.74 (95% CI: 0.66-0.81)] questionnaires had high reliability coefficients. The overall 
reliability of the PDQ-8 (Cronbach’s alpha coefficient) would not further improve by 
replacement of its items with other questions with higher internal consistency within each 
corresponding dimension in the original PDQ-39 [115]. The Persian-version of the PDQ-8 was 
shown to be a reliable instrument within different subgroups of IPD patients regarding age 
groups, sex, educational level and Hoehn & Yahr stage (Table 7). As illustrated in Figure 4, 
the scores of both PDQ-8 and PDQ-39 demonstrated significant discriminant values to 
distinguish different severity-related dummy conditions (all p<0.001). The mental scale of the 
UPDRS (part-I) was the only variable where the calculated AUC was larger for the PDQ-8 to 
discriminate the patients with score >1 (AUCPDQ-8=0.812, AUCPDQ-39=0.801; Figure 4-A). By 
contrast, the score from PDQ-39 had larger AUC to discriminate IPD patients with UPDRS-
motor domain (part-III) score >13 (AUCPDQ-8=0.632, AUCPDQ-39=0.670; Figure 4-B), UPDRS 
total score >30 (AUCPDQ-8=0.762, AUCPDQ-39=0.791; Figure 4-C), Hoehn & Yahr Stage >2 
(AUCPDQ-8=0.706, AUCPDQ-39=0.764; Figure 4-D) and Schwab & England ADL Score ≤80% 
(AUCPDQ-8=0.737, AUCPDQ-39=0.775; Figure 4-E).	  	  	  	  	  
 
4.3 Development of the screening instrument 
In study II, a comprehensive list of 25 potential screening items for parkinsonism (Table 9) was 
filled in 147 patients with IPD, 10 patients with atypical parkinsonism (AP), 7 patients with 
essential tremor (ET), 14 patients with dystonia, 19 patients with other neurologic disorders 
and 110 healthy controls. In most analyses, data from patients with IPD and atypical 
parkinsonism were merged to make a single group of patients with parkinsonism (n=157). As it 
is shown in Table 9, six items on “tremor & shaking” [CUI-=0.734 (95% CI: 0.730-0.738)], 
“troublesome arm swing” [CUI-=0.702 (95% CI: 0.698-0.706)], “stiffness & rigidity” [CUI-
=0.670 (95% CI: 0.666-0.675)], “feet stuck to floor” [CUI-=0.667 (95% CI: 0.663-0.671)], 
“slower daily activity” [CUI-=0.649 (95% CI: 0.644-0.654)] and “troublesome buttoning” 
[CUI-=0.643 (95% CI: 0.639-0.647)] demonstrated good utility (CUI≥0.64) to be included in 
the new screening tool for parkinsonism with the highest negative CUIs, respectively. Some 
other symptoms such as “changes in speech”, “smaller handwriting”, “shuffling & small 
steps”, “stooped posture” and “inexpressive face” showed a fair utility with a negative CUI 
ranging between 0.563 and 0.622.    
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A) UPDRS (Part I. Mental Disability) B) UPDRS (Part III. Motor Disability) 
C) UPDRS (Total score) D) Hoehn & Yahr Stage 
E) Schwab & England Activities of Daily 
Living (ADL) Score Figure 4. Receiver operating characteristics (ROC) 
curves to compare the diagnostic value of the PDQ-8 
(black line) and PDQ-39 (gray dotted line) to 
discriminate Parkinson’s disease patients with:  
A) UPDRS-mental score >1  
(AUCPDQ-8=0.812; AUCPDQ-39=0.801)  
B) UPDRS-motor score >13  
(AUCPDQ-8=0.632; AUCPDQ-39=0.670)  
C) UPDRS total score >30  
(AUCPDQ-8=0.762; AUCPDQ-39=0.791)  
D) Hoehn & Yahr Stage >2  
(AUCPDQ-8=0.706; AUCPDQ-39=0.764)   
E) Schwab & England ADL Score ≤80%  
(AUCPDQ-8=0.737; AUCPDQ-39=0.775)     
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Following selection of the best items, a new screening tool was developed consisting of the six 
symptoms with good negative CUI [88]. However, the discriminative performance of our new 
screening tool to distinguish patients with parkinsonism from healthy individuals was assessed 
in five different formats:  
1) Crude score of the 6-item instrument consisting of symptoms with good negative CUI  
2) Crude score of the 11-item instrument consisting of symptoms with either good or fair 
negative CUI 
3) Weighted score of the 6-item instrument using CUI 
4) Weighted score of the 6-item instrument using regression model [resulted in a 4-item 
weighted version as: 2*(“stiffness & rigidity in legs”)+5*(“tremor & 
shaking”)+5*(“troublesome arm swing”)+5*(“feet stuck to floor”)] 
5) Weighted score of the 6-item instrument based on prevalence   
Using ROC analysis, the optimal cut-off values for discrimination were calculated for each 
format (Figure 5).  
Having included questions from several different instruments, we were able to imply the same 
procedures on previously introduced screening tools for parkinsonism on our single database to 
compare their discriminative capacity (Figure 6).    
Results from ROC analysis confirmed that our new 6-item screening instrument had the 
highest AUC [0.977 (95% CI: 0.963-0.992)] to discriminate IPD patients from healthy 
individuals compared to other screening tools that were assessed in our study. Furthermore, the 
new screening instrument had significant AUC to distinguish parkinsonism with different 
severities from healthy condition as follows: 
1) Hoehn & Yahr ≤1 [AUC=0.952 (95% CI: 0.918-0.986)]  
2) 1< Hoehn & Yahr ≤2 [AUC=0.985 (95% CI: 0.971-0.999)]  
3) Hoehn & Yahr >2 [AUC=0.994 (95% CI: 0.985-1)] 
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Table 9. Diagnostic values and Clinical utility index (CUI) of each single item for screening (ruling-out) or case-finding (ruling-
in) of parkinsonism from healthy condition [The range mentioned in parenthesis represents the 95% confidence interval (CI) of the 
estimations] 
 
NO. Item Sensitivity  (%) 
Specificity  
(%) 
Youden 
Index Positive CUI Negative CUI 
1 Impaired Consciousness 16.9 (11.5-23.9) 95.3 (88.9-98.2) 0.12 0.142 (0.135-0.148)  ×× 
0.423 (0.418-0.427) 
 × 
2 Uncontrolled Movements of Limbs 71.7 (63.7-78.6) 83.6 (75.1-89.8) 0.55 
0.615 (0.611-0.620)  
ü 
0.570 (0.565-0.575)  
ü 
3 Changes in Speech 56.9 (48.6-64.8) 92.7 (85.7-96.6) 0.50 0.521 (0.515-0.526)  ü 
0.563 (0.558-0.568) 
 ü 
4 Paralysis of Face NS NS - NS NS 
5 Drooling from Mouth 19.0 (13.2-26.3) 95.5 (89.2-98.3) 0.15 0.162 (0.155-0.169)  ×× 
0.438 (0.433-0.442) 
 × 
6 Weakness of Limbs NS NS - NS NS 
7 Sensory Changes in Limbs NS NS - NS NS 
8 Stiffness & Rigidity in Legs 88.9 (82.5-93.2) 80.0 (71.1-86.8) 0.69 0.765 (0.763-0.768) üü 
0.670 (0.666-0.675) 
üü 
9 Tremor & Shaking 85.8 (79.1-90.7) 89.9 (82.3-94.6) 0.76 0.793 (0.790-0.795) üü 
0.734 (0.730-0.738) 
üü 
10 Smaller Handwriting 65.0 (56.3-72.8) 93.8 (86.5-97.5) 0.59 0.609 (0.603-0.614)  ü 
0.614 (0.609-0.619) 
 ü 
11 Trouble in Arising from Chair 42.5 (34.6-50.7) 82.7 (74.1-89.0) 0.25 0.329 (0.322-0.335)  ×× 
0.421 (0.415-0.426) 
 × 
12 Softer Voice 22.1 (16.0-29.6) 92.6 (85.5-96.5) 0.15 0.179 (0.172-0.186)  ×× 
0.421 (0.416-0.425) 
 × 
13 Shoulder Pain NS NS - NS NS 
14 Troublesome Buttoning 63.0 (54.8-70.5) 98.2 (92.9-99.7) 0.61 0.617 (0.612-0.622)  ü 
0.643 (0.639-0.647) 
üü 
15 Shuffling & Small Steps 69.0 (61.0-76.1) 91.2 (84.6-96.0) 0.60 0.637 (0.633-0.641)  ü 
0.622 (0.618-0.627) 
 ü 
16 Troublesome Arm Swing 72.7 (64.7-79.5) 98.1 (92.6-99.7) 0.71 0.714 (0.710-0.717) üü 
0.702 (0.698-0.706) 
üü 
17 Poor Balance 445.8 (37.8-54.0) 82.7 (74.1-89.0) 0.29 0.361 (0.355-0.368) × 
0.430 (0.425-0.435) 
 × 
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18 Feet Stuck to Floor 66.4 (58.3-73.8) 98.2 (92.9-99.7) 0.65 0.652 (0.647-0.656) üü 
0.667 (0.663-0.671) 
üü 
19 Stooped Posture 59.4 (51.2-67.1) 92.7 (85.7-96.6) 0.52 0.546 (0.541-0.551)  ü 
0.573 (0.569-0.578)  
ü 
20 Changes in Smelling Ability 23.5 (17.2-31.2) 90.0 (82.4-94.7) 0.14 0.180 (0.173-0.187)  ×× 
0.413 (0.408-0.417) 
 × 
21 Screaming Nightmares 42.6 (34.8-50.8) 74.5 (65.2-82.2) 0.17 0.299 (0.293-0.305)  ×× 
0.357 (0.352-0.363) 
×× 
22 Troublesome Concentration & Memory NS NS - NS NS 
23 Slower Daily Activity 85.8 (79.1-90.7) 80.9 (72.1-87.5) 0.67 0.741 (0.738-0.744) üü 
0.649 (0.644-0.654) 
üü 
24 Inexpressive Face 48.3 (40.0-56.7) 96.4 (90.4-98.8) 0.45 0.461 (0.455-0.468) × 
0.558 (0.554-0.563) 
ü 
25 Troublesome Walking 69.4 (61.1-76.7) 72.7 (63.3-80.6) 0.42 0.544 (0.540-0.549) ü 
0.465 (0.459-0.472) 
× 
CUI: clinical utility index, NS: Not significant 
×× very poor utility, × poor utility, ü fair utility, üü good utility 
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  A) B) 
C) D) 
E) 
Figure 5. Overlaid histogram plots of different formats/modifications of the new screening 
instrument’s score to discriminate parkinsonism (blue columns) from healthy condition (pink 
columns) in recruited participants (total n=267). The overlaid purple columns represent either 
false negative or false positive categorized individuals, and the dashed black lines show the 
optimal cut-point value for discrimination in each condition. 
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Figure 6. Overlaid histogram plots of different screening instruments’ scores to discriminate 
parkinsonism (blue columns) from healthy condition (pink columns) evaluated in our single 
database (total n=267). The overlaid purple columns represent either false negative or false 
positive categorized individuals and the dashed black lines show the optimal cut-point value 
for discrimination in each instrument. 
 
4.4 Prevalence of parkinsonism 
Using the new screening tool developed in study II, 157 individuals with an average age of 
64.5 (SD=10.9) yrs who were recruited through the community-based door-to-door survey 
were positively screened for parkinsonism in study III. This resulted in an age- and sex-
adjusted prevalence rate of 222.9/100,000 (95% CI: 160-300) and 285/100,000 (95% CI: 240-
329) based on real Tehran population and the “WHO World Standard Population”, respectively 
[42]. Other than the new 6-item instrument, we also calculated the prevalence rate for 
positively screened cases by other tools. The standardized prevalence rate based on the “WHO 
World Standard Population” varied between 104.2/100,000 (95% CI: 87.9-120.5) (using 
Tanner et al items [104]) and 296.0/100,000 (95% CI: 249.7-342.4) (using the SNES tool). 
The male/female ratio of probable parkinsonism was 1.62 and a significant increase in the 
screening rate was observed by increasing age (p=0.026 for trend, Figure 7).  
 
 
 
 
 
I) 
J) 
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Figure 7. Age- and sex-adjusted rates (/100,000) of screened cases suspicious of parkinsonism 
using different screening instruments in each age category 
 
4.5 Nutritional status in Parkinson’s disease 
4.5.1 Prevalence of malnutrition 
Nutritional status of the IPD patients enrolled from the Movement Disorders Clinic was 
assessed and compared with a group of age- and sex-matched controls using the Persian-
translated version of the MNA and anthropometric measurements in study IV. No significant 
difference was found neither in the mean of total MNA score [25.1 (SD=3.4) in IPD patients 
vs. 24.4 (SD=3.8) in controls, p=0.094] nor in the prevalence of malnutrition [2.1% (n=3) in 
IPD patients vs. 2.0% (n=3), p=0.228] between the two study groups. Another 37 (25.9%) IPD 
patients and 51 (35.2%) controls were at risk of malnutrition (p=0.228) [55]. Detailed 
comparisons of anthropometric measurements are shown in Figure 8 demonstrating no 
significant difference in the categories of BMI, MAC and CC between the IPD and control 
groups (all p>0.05).    
Although case and control groups were matched based on the mean age and gender 
distribution, educational level was significantly different between two study groups. Therefore, 
further subgroup analysis followed by multivariate statistic was performed to assess the 
probable confounding effect of this variable. As shown in Figure 9, among illiterate 
individuals the mean MNA score was significantly higher in IPD patients [24.19 (SD=2.18) vs. 
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21.93 (SD=3.42), p=0.040], whereas among the ones with high school or college/university 
education the mean of total MNA score was higher in the control group. Nevertheless, even 
after adjustment for educational level by multivariate analysis, no significant difference was 
found in the average of total MNA score between IPD patients and the controls (p=0.434).   
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Distribution of different categories of anthropometric measurements consisting of 
calf circumference (CC, p=0.814), mild-arm circumference (MAC, p=0.363) and body mass 
index (BMI, p=0.919) and the whole nutritional status based on the total score of Mini 
Nutritional Assessment (MNA, p=0.228) in healthy controls versus Parkinson disease patients 
 
 
 
 
 
 
 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Malnourished 
At Risk of Malnutrition 
Normal Nutritional Status 
BMI<19 kg/m2 
19≤BMI<21 kg/m2 
21≤BMI<23 kg/m2 
23≤BMI  kg/m2 
MAC<21 cm 
21≤MAC<22 cm 
22≤MAC cm 
CC<31 cm 
31≤CC cm 
Parkinson disease 
Patients 
Healthy Controls 
Figure 9. Error bars for comparison of the 
total score of Mini Nutritional Assessment 
(MNA) between Parkinson disease patients 
and healthy controls within the subgroups 
of educational level (Illiterate: p=0.040; 
primary and/or secondary school: p=0.574; 
high school/diploma: p=0.351; university: 
p=0.921) (* statistical significant 
difference) 
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4.5.2 Determinants of malnutrition 
In study V, the association between nutritional status and a comprehensive list of motor and 
non-motor features of PD was evaluated in 146 IPD patients from the Movement Disorders 
Clinic. Forty patients were either malnourished or at risk of malnutrition. Table 10 shows the 
findings for univariate comparisons of the baseline, HRQoL, disease severity and psychiatric 
features between the two groups of IPD patients regarding nutritional status. IPD patients with 
abnormal nutritional status had a significantly higher score not only for the entire UPDRS 
[45.9 (SD=18.0) vs. 26.4 (SD=13.6), p<0.001] but also for all of its parts (all p<0.05). Among 
the NMS, more severe anxiety [8.8 (SD=5.2) vs. 5.9 (SD=4.9), p=0.002], depression [9.0 
(SD=4.2) vs. 3.6 (SD=3.5), p<0.001] and fatigue [5.4 (SD=1.5) vs. 4.2 (SD=2.0), p<0.001] 
were recorded in those with abnormal nutritional status. Except for stigma, all other domains of 
HRQoL were significantly poorer among those with abnormal nutritional status (all p<0.05) 
[73]. Even though total MNA score was not significantly associated with patients’ age 
(r=0.021, p=0.805), it inversely correlated with disease duration (r=-0.249, p=0.002) such that 
those with longer PD duration had worse nutritional status (Figure 10).   
Two multivariate regression models were applied to investigate the independent predictors of 
total MNA score (as a continuous outcome) and being either malnourished or at risk of 
malnutrition (as a binary outcome). As it is summarized in Table 11, depression (standardized 
coefficient=-0.352, p<0.001), total UPDRS score (standardized coefficient=-0.313, p<0.001), 
patients’ sex (standardized coefficient=-0.196, p=0.003) and weight-adjusted daily levodopa 
dosage (standardized coefficient=-0.190, p=0.006) were the strongest independent 
determinants of total MNA score after multivariate adjustments. Results from model 2 revealed 
that each unit of increase in the Hoehn and Yahr stage and depression score accompanied with 
a 2.4-time (95% CI: 1.3-4.5, p=0.007) and 1.4-time (95% CI: 1.2-1.6, p<0.001) higher 
likelihood of being malnourished or at risk of malnutrition in IPD patients, respectively [73]. 
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Table 10. Comparison of the mean [standard deviation (SD)] scores of different motor, non-
motor and quality of life (PDQ-39) scales between subgroups of Parkinson disease (PD) 
patients regarding nutritional status (MNA) 
 
Scale Domain 
Malnourished or  
at risk of 
malnutrition 
(n=40) 
Normal 
nutritional 
status 
(n=106) 
p-value  
(t test) 
B
as
el
in
e 
Age (yr) 61.3 (12.3) 61.3 (9.8) 0.982 
Disease duration (yr) 8.2 (6.9) 6.2 (4.6) 0.045* 
Body mass index (BMI) 
(kg/m2) 23.9 (3.8) 26.6 (4.3) 0.001* 
Daily levodopa dose (mg) 817 (450) 841 (490) 0.789 
PD
Q
39
 
Mobility 45.6 (26.6) 19.4 (20.7) <0.001* 
Activities of daily living 
(ADL) 38.4 (28.9) 18.0 (17.9) <0.001* 
Emotional well-being 41.3 (22.4) 22.1 (20.8) <0.001* 
Stigma 22.0 (24.4) 21.5 (25.4) 0.913 
Social support 13.0 (17.2) 5.1 (10.9) 0.016* 
Cognitive impairment 25.5 (20.5) 13.5 (16.6) <0.001* 
Communication 24.6 (23.9) 10.3 (13.6) 0.001* 
Bodily discomfort 32.5 (20.3) 16.4 (19.6) <0.001* 
D
is
ea
se
 S
ev
er
ity
 
UPDRS: Part I-mental 3.8 (3.2) 1.3 (1.4) <0.001* 
UPDRS: Part II-ADL 15.9 (7.8) 9.4 (5.8) <0.001* 
UPDRS: Part III-motor 20.6 (10.1) 13.3 (7.4) <0.001* 
UPDRS: Part IV-
complications 
a. Dyskinesia 
b. Wearing off 
5.1 (3.4) 
1.7 (2.5) 
2.3 (1.4) 
2.9 (2.2) 
.8 (1.4) 
1.5 (1.2) 
<0.001* 
0.042* 
0.003* 
UPDRS: Total 45.9 (18.0) 26.4 (13.6) <0.001* 
Hoehn & Yahr stage# 2.5 (.8) 1.8 (.8) <0.001* 
Schwab & England stage (%) 71.2 (19.6) 85.7 (13.9) <0.001* 
H
A
D
S Anxiety 8.8 (5.2) 5.9 (4.9) 0.002* 
Depression 9.0 (4.2) 3.6 (3.5) <0.001* 
FS
S 
Fatigue 5.4 (1.5) 4.2 (2.0) <0.001* 
# Values are presented as median [interquartile range (IQR)] 
*	  Statistically significant (p-value<0.05) 
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Figure 10. Scatter plot of the correlation between total score of Mini Nutritional 
Assessment (MNA) and: A) patients’ age (r=0.021, p=0.805); B) disease duration (r=-
0.249, p=0.002) in Parkinson disease patients 
 
 
A) 
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4.6 Quality of life in Parkinson’s disease 
Univariate associated factors and multivariate determinants of HRQoL in total IPD population 
(n=157) who were recruited from the Movement Disorders Clinic were assessed in study VI. 
Further analyses were performed to investigate the potential heterogeneity in the role of these 
factors and general pattern of HRQoL between different phenotypes of IPD patients.    
4.6.1 Univariate correlates 
Several baseline characteristics, motor severity and subtypes, and NMS significantly correlated 
with PDSI as a single indicator of HRQoL. Patients with lower tremor score [unadjusted 
coefficient=-0.26 (95% CI: -0.44–-0.08)], fall [unadjusted coefficient=12.15 (95% CI: 7.56-
16.74)], freezing [unadjusted coefficient=13.33 (95% CI: 8.67–18.00)], more symmetric 
Table 11. Multivariate regression models to determine the motor and non-motor factors 
independently related to total score of the MNA questionnaire (model 1) and having abnormal 
versus normal nutritional status (model 2) in recruited Parkinson disease (PD) patients (In 
both regression models, age at the time of diagnosis, sex, weight-adjusted levodopa dosage, 
the score of the each part of the UPDRS scale, total UPDRS score, Hoehn & Yahr stage, 
Schwab & England ADL score, anxiety, depression and fatigue scores were entered as the 
predictor list.) 
 
Model 1: Linear regression  
(Dependent variable: total MNA score) 
Significant Variables 
Unstandardized 
Coefficients 
Standardized 
Coefficients t p-value 
B SEM Beta 
Gender -1.53 0.50 -0.20 -3.03 0.003* 
Weight-adjusted 
levodopa dosage -0.09 0.03 -0.19 -2.82 0.006* 
Depression score -0.29 0.06 -0.35 -4.55 <0.001* 
Total score of UPDRS -0.06 0.02 -0.31 -3.90 <0.001* 
Constant 30.15 0.50 - 59.87 <0.001* 
Model 2: Binary Logistic regression  
(Dependent variable: abnormal vs. normal nutritional status) 
Significant Variables B SEM OR  (95% CI) Wald p-value 
Depression score 0.35 0.07 1.42 (1.24-1.64) 24.26 <0.001* 
Hoehn & Yahr stage 0.87 0.32 2.38 (1.26-4.46) 7.23 0.007* 
Constant -4.98 0.97 - 26.33 <0.001* 
SEM: standard error of mean, CI: confidence interval, OR: odds’ ratio   
*	  Statistically significant (p-value<0.05) 
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disease [unadjusted coefficient=-18.91 (95% CI: -29.10–-8.72)], cognitive impairment 
[unadjusted coefficient=7.98 (95% CI: 2.82–13.14)], hallucinations [unadjusted 
coefficient=16.66 (95% CI: 9.68–23.63)], apathy [unadjusted coefficient=12.75 (95% CI: 
8.12–17.39)], sleep disturbances [unadjusted coefficient=8.93 (95% CI: 4.09–13.77)], higher 
depression [unadjusted coefficient=2.47 (95% CI: 2.07–2.87)], anxiety [unadjusted 
coefficient=1.75 (95% CI: 1.36–2.14)] and fatigue [unadjusted coefficient=3.63 (95% CI: 
2.47–4.79)] scores, and worse nutritional status [unadjusted coefficient=-2.41 (95% CI: -3.05–-
1.77)] had worse HRQoL indicated by a higher PDSI. 
4.6.2 Multivariate determinants 
The tolerance statistics were all >0.40 and the VIF<2.5 demonstrating no serious problem with 
the collinearity issue in all multivariate regression models. As it is summarized in Table 12, 
anxiety [adjusted coefficient=0.51 (95% CI: 0.15–0.87)], depression [adjusted coefficient=1.11 
(95% CI: 0.63–1.59)] and UPDRS-part II (ADL) [adjusted coefficient=0.90 (95% CI: 0.60–
1.20)] scores were the significant independent determinants of PDSI after adjustment for sex, 
level of education, comorbidity score and PD duration as the baseline covariates.  
Considerable differences were found in the determinants’ list of each HRQoL domain. Female 
sex, higher depression score and more impaired ADL were significant predictors of worse 
HRQoL in “mobility” and “social support” domains (all adjusted coefficients>0 and p<0.05). 
“Emotional well-being” was significantly worse in IPD patients who were female [adjusted 
coefficient=7.18 (95% CI: 1.02–13.34)], scored higher for anxiety [adjusted coefficient=1.65 
(95% CI: 0.98–2.31)] and depression [adjusted coefficient=1.99 (95% CI: 1.11–2.88)] and had 
less severe motor signs [adjusted coefficient=-0.53 (95% CI: -0.93–-0.12)]. More severe 
anxiety [adjusted coefficient=1.15 (95% CI: 0.20–2.10)], more impaired ADL [adjusted 
coefficient=0.85 (95% CI: 0.07–1.64)] and less severe motor signs [adjusted coefficient=-0.57 
(95% CI: -1.15–0.01)] were the strongest determinants of “stigma”. Higher number of 
comorbidities [adjusted coefficient=2.63 (95% CI: 0.02–5.24)] accompanied with a worse 
“cognition” dimension of the HRQoL and “communication” was mostly affected by depression 
[adjusted coefficient=1.33 (95% CI: 0.49–2.17)] and motor symptoms [adjusted 
coefficient=0.81 (95% CI: 0.29–1.33)] in IPD patients.    
4.6.3 Structural equation model 
As it is illustrated in Figure 11, the best SEM consisted of two major latent exogenous 
variables to characterize the global “motor” and “non-motor” components of PD, and the eight 
dimensions of the PDQ-39 questionnaire were indicated by an endogenous latent variable 
representing the general HRQoL. This model had 267 degrees of freedom and a Chi square 
value of 557 (Chi2/df=2.1, p<0.001). 
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With RMSEA=0.08, NFI=0.74, CFI=0.84 and TLI=0.82, the model could explain 89% of the 
variance of total HRQoL. All standardized regression weights were statistically significant 
(p<0.05). Three direct correlations (between cognition and hallucination in the non-motor 
section, anxiety on “emotional well-being” dimension of HRQoL, “social support” and 
“communication” dimensions of HRQoL) were added in order to improve the model. In the 
entire study population, non-motor latent domain had a larger direct effect on HRQoL 
compared to that of the motor (SRW=0.69 vs. 0.32), while the motor domain showed an 
indirect effect mediated through the non-motor section as large as 0.49 resulting in the total 
effect of 0.81 from the motor domain on HRQoL. ADL (SRW=0.94), motor signs (SRW=0.70) 
and falling (SRW=0.70) were the strongest indicators of the motor latent variable.  
Table 12. Multivariate linear regression model to find the baseline and clinical predictors of 
the Parkinson disease summary index (PDSI) as a single indicator for health-related quality of 
life (HRQoL) in Parkinson disease patients 
  
Independent 
Variables 
Unstandardized 
Coefficients 
(95% CI) 
Standardized 
Coefficients p-value 
Collinearity 
Statistics 
Tolerance VIF 
Female Sex 5.30  (1.97 – 8.62) 0.16 0.002* 0.83 1.21 
Disease Duration  -0.24  (-0.54 – 0.07)  -0.08 0.127 0.78 1.29 
Comorbidity Score  1.33  (-0.15 – 2.81) 0.08 .079 0.97 1.03 
Anxiety Score 0.51  (0.15 – 0.87) 0.17 .006* 0.59 1.70 
Depression Score 1.11  (0.63 – 1.59)  0.32 <0.001* 0.45 2.21 
MNA Total Score -0.14  (-0.71 – 0.43) -0.03 0.634 0.57 1.77 
Fatigue Score 0.33  (-0.58 – 1.24) 0.04 0.48 0.67 1.50 
UPDRS Score 
Part I-items 1, 2, 4 
 
Part II- ADL 
 
Part III- Motor 
 
0.69  
(-0.20 – 1.57) 
0.90  
(0.60 – 1.20) 
-0.12  
(-0.34 – 0.10) 
 
0.08 
 
0.43 
 
-0.07 
 
0.127 
 
<0.001* 
 
0.269 
 
0.71 
 
0.41 
 
0.49 
 
1.41 
 
2.42 
 
2.05 
Constant 3.66  (-13.40 – 20.72) - .672 - - 
CI: confidence interval, VIF: variance inflation factor   
*	  Statistically significant (p-value<0.05) 
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Figure 11. Structural equation model for the factors affecting health-related quality of life 
(HRQoL) in patients with Parkinson disease [all standardized regression weights are 
statistically significant at p<0.001 except for the effect of comorbidities on HRQoL  
(p=0.045), the indication of motor domain on fluctuations (p=0.062) and  
dyskinesia (p=0.001), and the indication of HRQoL on stigma (p=0.001)] 
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Psychosocial functioning (SRW=0.84), depression (SRW=0.82) and anxiety (SRW=0.63) were 
the most determinant factors for the non-motor latent domain to affect HRQoL. The same 
hypothetical SEM was re-structures in subgroups of PD with different phenotypes regarding 
onset-age, progression and dominant symptom. Figure 12 illustrates the heatmap for the SRWs 
from the phenotype-specific SEMs. The intensity of colors represents the magnitude of each 
association in the SEM for each PD phenotype. The strength of the main associations and 
indicators of the latent variables were heterogeneously different for each phenotype.             
Motor domain showed larger direct impact on HRQoL compared to non-motor section in 
younger-onset (SRW=0.61, p<0.001) and rapid-progression PD (SRW=0.57, p<0.001), 
whereas among typical-onset, slow-progression, tremor and non-tremor-dominant PD, non-
motor domain had larger direct effect (all p<0.05). In patients with slow-progression PD, non-
motor domain showed the largest direct effect (SRW=0.95, p=0.005) on HRQoL and all of the 
effects of motor domain was mediated through non-motor section. Comorbidity profile showed 
significant effect on HRQoL only among those with >50 years of age at the time of diagnosis 
(SRW=0.14, p=0.007) and non-tremor-dominant PD (SRW=0.13, p=0.037).  
Obvious heterogeneities were also noted in the indicators profile of each phenotype. In 
younger-onset patients, depression was the strongest driver of the non-motor latent variable 
(SRW=0.91, p=0.004). Sleep disorder was a significant indicator for non-motor domain to 
affect HRQoL only among older-onset (SRW=0.33, p=0.004), slow-progression (SRW=0.32, 
p=0.031) and non-tremor (SRW=0.37, p=0.008) phenotypes. Opposite to the rapid-progression 
phenotype, fatigue was a significant indicator for non-motor domain among the slow-
progression PD patients (SRW=0.49, p=0.010). In contrast to all other phenotypes, both 
dyskinesia (SRW=0.42, p=0.012) and fluctuations (SRW=0.33, p=0.043) showed significant 
contributions in the motor domain to affect HRQoL among the younger-onset patients. 
Regarding different indicators of HRQoL, “cognition” showed the highest SRW among the 
older-onset patients (0.72), whereas “mobility” had the largest SRW in younger-onset PD 
phenotype (0.90).   
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Figure 12. Heatmap of the standardized direct regression weights (SRW) from the structural equation models (SEM) to evaluate factors 
affecting health-related quality of life (HRQoL) and the indicators of motor domain, non-motor domain and HRQoL in different  
phenotypes of Parkinson disease patients [the intensity of colors represents 0.2 unit (one quintile) increase in SRW for each section] 
	  
!
M
ai
n 
A
ss
oc
ia
tio
ns
 Exogenous variable 
(Independent) ! 
Endogenous variable 
(Dependent) 
Onset-Age Progression Dominant Symptom 
≤50 yr >50 yr Slow Rapid Tremor Non-Tremor 
Motor Domain  !  HRQoL       
Non-Motor Domain  ! HRQoL       
Comorbidities ! HRQoL       
Motor Domain ! Non-Motor Domain       
 
In
di
ca
to
rs
 o
f l
at
en
t v
ar
ia
bl
es
 
Motor Domain 
! UPDRS-ADL       
! UPDRS-Motor Signs       
! Dyskinesia       
! Fluctuations       
! Falls       
! Freezing       
! Hoehn & Yahr Stage       
Non-Motor Domain 
! Depression       
! Anxiety       
! Cognition       
! Hallucination       
! Apathy       
! Fatigue       
! Psychosocial Functioning       
! Sleep Disturbances       
! Nutritional Status       
HRQoL 
! Mobility       
! ADL       
! Emotional Well-being       
! Stigma       
! Social Behaviors       
! Cognition       
! Communication       
! Bodily Discomfort       
DISCUSSION	   60	  
	  
5 DISCUSSION
5.1 Summary and interpretations of the main findings 
5.1.1 Questionnaire validations 
Through validation studies, we showed that the Persian-translated versions of the FSS [110], 
SCOPA-PS [112], MNA [113], PDQ-39 and PDQ-8 [115] were trans-culturally reliable and 
valid to assess fatigue, psychosocial functioning, nutritional status and HRQoL in Iranian PD 
patients, respectively (Table 6). These scales were also proved to be reliable and valid within 
different subgroups regarding age category, sex, educational level and PD severity. More 
specifically about the PDQs, we demonstrated that the composition of the items in the short-
form version (PDQ-8) was appropriate enough to validly assess different aspects of HRQoL 
especially the mental and behavioral domains [115], which is in line with a previous report 
[129]. Literature review on other studies showed that the Cronbach’s alpha coefficient of the 
PDQ-8 was between 0.72 and 0.88, which is lower than the long-form version (PDQ-39). Our 
reliability coefficient (0.74) is close to the Greek (0.72) [130], Italian (0.72) [131] and English 
version in Canadian (0.72) [132] and Singaporean (0.75) [133] PD populations while some 
other studies showed higher alpha coefficients for the reliability of the PDQ-8 [129, 134-136].             
5.1.2 Novel screening instrument for parkinsonism 
In study II, a new screening instrument was developed containing six items, three of which 
refer to the cardinal symptoms on “stiffness & rigidity”, “tremor & shaking” and “slower daily 
activity” and three others namely “troublesome buttoning”, “troublesome arm swing” and “feet 
stuck to floor” [88]. In line with previous studies [99, 107, 137], tremor had the highest 
diagnostic value as a single symptom to discriminate parkinsonism from healthy condition. 
Using the new concept of CUI to select the best screening symptoms, our new 6-item 
instrument showed the strongest diagnostic value to screen parkinsonism in comparison with 
the previously developed tools [88]. Our newly developed instrument showed the highest 
Youden’s index (0.861) and specificity (96%), while, the WHO recommended questionnaires 
[102-103] had a higher sensitivity (95%) but lower specificity (60% and 72%). Our new 
instrument also showed the highest overall accuracy with an AUC of 0.977 compared to others 
including the SNES [99] (0.934), WHO modified instrument [102] (0.933), recommended 
index by Daurte et al [105] (0.947), Setthawatcharawanich et al [107] (0.950) and Chan et al 
[106] (0.968) to screen parkinsonism. Further subgroup analysis demonstrated that our new 
instrument remains valid for screening of parkinsonism within different age categories and 
severity of symptoms. In other words, it can accurately screen individuals suspicious of 
parkinsonism even with young age and mild symptoms during the early-stage of their disease. 
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5.1.3 Prevalence of parkinsonism and Parkinson’s disease 
Using our newly developed screening instrument in the first community-based doo-to-door 
neuroepidemiologic survey on parkinsonism in Tehran, Iran, the adjusted screening-detected 
prevalence rate was found to be 223/100,000 and 285/100,000 based on Tehran and “WHO 
World Standard” populations, respectively [42]. Both estimations could be considered as 
medium-to-high compared with other countries (Table 2). Previous surveys demonstrated that 
around 58-70% of the positively screened cases for parkinsonism actually have PD [5-6, 29, 
138-140]. Accordingly, it could be expected that PD prevalence in Tehran urban population 
could be expected to range between 129-156/100,000 (standardized by Tehran population) or 
165-199/100,000 (standardized by “WHO World Standard Population”). This rate is in 
between of the wide range of PD prevalence estimated for Caucasians populations (65-
257/100,000) [37]. Focusing more on the Middle East where Iran is located, a higher PD 
prevalence is seen in Egypt, Tunisia and Turkey, Iran is in the middle range and Saudi Arabia 
has the lowest estimation (Table 2). There is another study to investigate PD prevalence in 
Persian ethnic group that has been done on the Parsi community (group of Persians who 
migrated from Iran to South Asia between the seventh and tenth centuries A.D.) in Bombay, 
India [32]. Bharucha et al showed that PD prevalence is higher among these Persians 
(192/100,000) who live in India compared to the highest rates reported for Indians themselves 
[141]. Interestingly, the prevalence rate of PD in Parsi population of India is much closer to 
our estimations from Iran. Nonetheless, not only ethnicity but also various environmental 
factors may play role to have such a varied prevalence features for PD. In China, a tenfold 
difference in PD prevalence has been shown from a nationwide survey covering different parts 
of the country highlighting the role of environmental factors as well [35]. In our study, 
prevalence of suspicious parkinsonism increased by advancing age and the overall male/female 
ratio was 1.62 [42], which is quite similar to one report from Norwegian PD population (1.58) 
[142].         
5.1.4 Nutritional status in parkinsonian patients 
Using the validated version of the MNA, similar proportion of both PD patients and controls 
(2.1% vs. 2%) were detected to be malnourished in study IV and the mean MNA score was not 
significantly different between the two groups [55]. In line with previous reports from the 
Chinese and Italian PD populations that have used MNA as well [60-61], close to a quarter of 
Iranian PD patients were found to be at risk of malnutrition. The unexpected low rate of severe 
malnutrition in all of these populations [55, 60-61] is believed to mainly stem from the source 
of patient selection. All patients were recruited from outpatient clinics where disabled in-
hospitalized cases were not included and majority of the samples were in the mild-to-moderate 
stages of PD. In the Chinese PD population, malnutrition was observed only in 1.7% and such 
a low rate was attributed to race, age, Hoehn and Yahr stage and disease duration [60]. In 
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another Italian survey, underweightness was also reported to be uncommon in PD patients and 
the authors concluded that the general overweightness in industrialized countries and the 
modern antiparkinson therapies might be possible reasons [143]. Specifically in our study, 
another issue might have also contributed to the rather low and similar prevalence rate of 
malnutrition compared to the controls, which is related to the cultural behaviors and values in 
Iranian society. The family members, spouses and caregivers of the elderly patients usually pay 
more attention to elderly patients including providing appropriate nutritious diet for them when 
they are sick. The patients with mild to moderate stages of PD mostly live with their own 
families at their homes where they can benefit from these extra supports. Otherwise, it seems 
that elderly PD patients who are living alone may face difficulties in food preparation and 
appropriate nutrition on their own [55]. Regardless of all of these interpretations, it is important 
to bear in mind that almost one third of Iranian PD population in study IV were either at risk of 
malnutrition or malnourished, the fact which should be considered for a more efficient 
management strategy. 
Among the anthropometric measurements, CC was in average smaller in PD patients compared 
to the controls [55], which might be due to the excess adiposity and depletion of lean body 
mass in PD [144]. BMI has been typically used as another indicator for nutritional status in PD 
population. However, different cut-off values have been applied to define malnutrition based 
on BMI ranging from 18.6 kg/m2 [70] to 22 kg/m2 [67] in different reports. One longitudinal 
study showed that 15.6% of PD patients versus 5.1% of the controls developed malnutrition, 
which was defined as BMI<22 kg/m2 [67]. Using a lower cut-off point as BMI<20 kg/m2, 
prevalence of malnutrition was shown to be 19.5% and 9.3% in urban or rural PD populations, 
respectively [145]. In our study, 11.2% of the PD patients had BMI<21 kg/m2, which was close 
to that of the matched controls (10.3%) [55]. A recent meta-analysis showed that PD patients 
had a significantly lower BMI than controls, and patients with Hoehn and Yahr stage 3 had 
even lower BMI compared to those at stage 2 [146]. This can explain why we did not find any 
difference in the average BMI values between the controls and PD patients who were mostly in 
stage 2 or less in our study [55].   
Results from study V demonstrated that several demographics, motor and non-motor features 
associated with nutritional status in PD patients (Table 3). PD patients with nutritional 
insufficiency had more severe symptoms in all parts of the UPDRS scale namely motor, non-
motor, ADL and complications [73]. Both dyskinesia and wearing-off phenomenon were more 
common among PD patients with abnormal nutritional status [73]. This finding is aligned with 
another study that reported dyskinesia as an important determinant of anthropometric 
measurements in a group of PD patients with more advanced stage than our study population 
[70]. We observed more severe depression and anxiety in PD patients with nutritional 
problems, which is quite in line with several previous studies on different PD populations [60, 
69]. Our study is the first to show a strong univariate association between fatigue and 
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nutritional status in PD patients, however, no causal inference were made since fatigue and 
exhaustion could potentially be considered as both cause and consequence of malnutrition [73]. 
Following multivariate adjustment, female sex, higher weight-adjusted daily levodopa dosage, 
more severe disability (higher total UPDRS score, more advanced Hoehn and Yahr stage) and 
more severe depression independently predicted lower MNA score representing a higher risk 
of nutritional insufficiency in people with PD [73]. Female PD patients had significantly worse 
nutritional status even after statistical adjustment for other covariates, which is in line with 
previously published reports indicating female sex as a risk factor for malnutrition in the 
elderly based on the total MNA score [147], or PD patients using anthropometric indices [66, 
71]. Similar to some previous reports [69, 71, 148], we also could not find any association 
between nutritional status and daily dosage of levodopa. Nevertheless, when the cumulative 
daily dosage of levodopa was adjusted for body weight (mg per kg body weight), it 
significantly correlated with the total MNA score in ours [73], Sheard et al’s [69] and 
Barichella et al’s [68] studies. Interestingly, while no association was found between patient’s 
age and total MNA score, longer disease duration accompanied with worse nutritional status in 
PD patients.  
In study V, we also showed that nutritional status strongly affected HRQoL. PD patients who 
were malnourished or at risk of malnutrition had poorer life quality in all domains of PDQ-39 
except for stigma. To our knowledge, our study was one of the few that directly assess the 
relationship between nutritional status and HRQoL using MNA and PDQ-39 in PD patients. 
Similar association has been previously shown in another elderly population from 
rehabilitation centers [52].  
5.1.5 Quality of life in Parkinson’s disease 
In study VI, female sex, lower level of education, higher number of comorbid conditions and 
longer duration of disease were demographic characteristics that adversely affected HRQoL. 
Through univariate analysis, several motor and non-motor features were found to significantly 
influence HRQoL in our study population. PD patients with more severe motor disabilities 
(both responsive and non-responsive to levodopa), higher dependency in their daily lives, 
lower tremor score, more symmetric subtype, higher freezing, fall and more severe gait 
disturbances experienced poorer HRQoL. Cognitive impairment, hallucination, apathy, sleep 
disturbances, anxiety, depression and fatigue were detected as the non-motor drivers of 
HRQoL. Interestingly, worse nutritional status and less psychosocial activity also accompanied 
with poorer HRQoL in people with PD as shown in study VI. Following multivariate analysis, 
motor symptoms affecting activities of daily life, depression, anxiety and female sex were 
found to be the strongest independent determinants of HRQoL in Iranian PD population, 
respectively. In domain-specific analyses, PD patients with a higher number of comorbidities 
had in average a 2.6 poorer score in cognitive dimension. Mental and behavioral symptoms 
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such as apathy, cognitive impairment and hallucination adversely affected cognition and bodily 
discomfort dimensions of the HRQoL in parkinsonian patients. Noteworthy, less severe motor 
signs (UPDRS-Part III) associated with worse emotional-well being and stigma scores showing 
that these domains are mainly affected at the early stages of PD and coping mechanisms during 
the next years could improve these aspects of HRQoL in parkinsonian patients.  
In line with our findings, non-motor symptoms, higher motor severity shown by Hoehn and 
Yahr score and UPDRS-Part III, motor complications, female sex, longer disease duration and 
being single or divorced have been shown to negatively affect the overall HRQoL in a 
population of Chinese PD patients which is quite similar to ours regarding the average PDSI 
(21.2 vs. 21.7) [83]. Similarly, they have also found that NMSs are the main determinants of 
HRQoL in all dimensions. However, they have used the non-motor symptoms scale of 
Parkinson's disease (NMSS) as a general instrument for NMSs [83], while we have evaluated 
them with more specific tools and shown that depression and anxiety are probably the main 
non-motor drivers of HRQoL in PD patients. Several other studies have also concluded that 
NMSs were the main determinant factors for HRQoL [74, 79-81, 83, 149-150], and some have 
specified depression and anxiety as the most important responsible factors for poor HRQoL in 
parkinsonian patients [150-153]. PD severity and disability indicators such as ADL and level 
of dependency have been commonly shown to be another important driver of worse HRQoL in 
PD patients [76, 154], which is consistent with the independent role of UPDRS-ADL score 
found in our investigation. Female sex as a risk factor for poorer HRQoL in PD has been 
previously shown [83, 155-157], yet with some controversial findings in some other studies 
[79, 82, 158]. Although a worse life quality in women with a chronic disease can be generally 
attributed to the rather higher burden of depression and anxiety, our study demonstrated that 
female sex remained an independent risk factor for poor HRQoL in PD even after adjustment 
for psychiatric symptoms and their severities. 
Using the concept of structural modeling, we demonstrated that the best hypothesized 
structural causal model in the whole PD population consisted of motor, non-motor and 
comorbidity components, which could explain up to 89% of the variance in HRQoL indicator. 
UPDRS-Part II, UPDRS-Part III and falling were found to be the most important indicators for 
the global motor component, while depression and psychosocial functioning were the strongest 
indicators for the global non-motor component. As it is illustrated in Figure 11, anxiety had a 
direct and strong effect on emotional well-being domain of HRQoL in PD patients and seemed 
to be its main determinant. Our investigation revealed that nutritional status and fatigue played 
a key independent role in the non-motor component to affect HRQoL in PD. Other motor and 
gait complications such as dyskinesia, fluctuations and freezing were all independent indicators 
of the global motor component in the pathway to affect HRQoL. However, a substantial 
proportion of the overall contribution of motor symptoms in HRQoL was mediated through the 
non-motor component. We found outstanding heterogeneities in the structural model of 
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HRQoL in different PD phenotypes (Figure 12). Interestingly, the comorbidity component was 
shown to be an important determinant of HRQoL only among those with either older-onset or 
non-tremor-dominant PD. Among the patients with rapid progression PD, a chronicity 
symptom such as fatigue was not a significant indicator of the non-motor section, while the 
motor component had a larger direct effect on HRQoL. In contrast, the impact of motor 
component on HRQoL was mostly mediated through the non-motor component, as the main 
driver of HRQoL in slow-progressive PD. Contribution of global motor component in HRQoL 
was remarkably different between the younger-onset and older-onset PD patients such that the 
importance of direct effects of motor symptoms on HRQoL was three-time larger in younger-
onset patients. As an important marker of HRQoL, sleep disorders showed significant 
contribution in the global non-motor component only among the older-onset, slow-progression 
and non-tremor-dominant phenotypes. 
So far, a few studies have used SEM to comprehensively evaluate the pattern of HRQoL in PD 
[159-160]. In one study, depression had the largest contribution in HRQoL followed by axial 
motor, gastrointestinal, and urinary symptoms, and psychosocial well-being showed a stronger 
impact compared to physical functioning [159]. According to their recommended SEM, other 
symptoms such as pain, psychiatric complications, motor symptoms, autonomic dysfunction, 
motor complications and daytime sleepiness, indirectly affect HRQoL via psychosocial well-
being and ADL [159]. Using path analysis in another study, direct contribution of self care-
related factors such as functional disability and falls has been shown in HRQoL of people with 
PD [160]. More recently, another SEM has been proposed in which depression and pain were 
the main factors that could directly affect HRQoL in PD [161]. Even though different structural 
models have been hypothesized, our findings on the general model are aligned with them. In all 
SEMs, either functional disabilities or psychiatric well-being such as depression have been 
pointed out as the most consistent factors associated with poorer HRQoL in PD patients. 
Nevertheless, there are some differences in the list of variables that have been used to create 
these models and none of them have compared the model between different PD phenotypes. 
Some previous studies have compared HRQoL between younger-onset and older-onset PD 
patients using regression analysis where more severe depression and more impaired emotional 
domain of HRQoL have been shown in younger-onset PD patients [157, 162]. In line with 
these findings, our study also demonstrated a more prominent role for depression in the global 
non-motor component to affect HRQoL among PD patients with earlier age of onset.           
  
5.2 Methodological considerations 
5.2.1 Limitations 
We acknowledge the limitations of our project that are categorized as the following topics: 
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• Study design: Cross-sectional design is the major obstacle for interpretation on 
causality between the hypothetical exposures and outcomes. Therefore, we have 
mostly concluded on associations and/or correlations. In study V, no causal 
relationship could be concluded between nutritional status and its determinants 
since the outcome of interest (malnutrition) and associated factors were all assessed 
at the same time point. Therefore, it is not clear whether malnutrition is the cause or 
the effect or in other words, “the chicken or the egg” [163]. In a cross-sectional 
study, the relationship between PD symptoms and nutritional status remains 
reciprocal. While poor management of PD symptoms can increase the risk of 
malnutrition, poor dietary status can itself result in worse symptoms [73].	        
• Generalizability: We used data collected from an outpatient Movement Disorder 
Clinic in study I, study II, study IV, study V and study VI. In this setting, fewer 
patients with advanced stages of PD are usually recruited leading to a potential 
selection bias that might restrict generalizability of the findings mainly to mild-to-
moderate PD patients. In study III, one should consider that though Persians are the 
major ethnic group, Tehran population is a mixture of different ethnicities 
consisting of Persian, Azeri, Kurdish and even immigrant sub-populations namely 
Afghan and Iraqi. As a result, our findings on the prevalence of parkinsonism are 
more appropriately generalized to Iranian urban population as a geographic entity 
rather than Persian ethnic group [42].   
• Internal validity: Due to limited resources, lack of a confirmatory assessment in a 
phase II study by well-trained neurologists is the major weakness of study III. Even 
though the screening instrument showed quite high diagnostic value, the positively 
screened individuals for parkinsonism in study III still need to be re-evaluated by 
expert neurologists for final diagnosis of parkinsonism following physical 
examination. With respect to this limitation, all prevalence features in study III were 
expressed as screening-detected suspicious parkinsonism. In study IV and study V, 
no blood sample was collected to quantify serum indicators of malnutrition such as 
albumin. Nonetheless, MNA is now considered as an innovative clinical instrument 
that provides valid information on several aspects of nutritional status containing 
four anthropometric measurements with no need for further blood tests and other 
clinical evaluations [55]. MNA has been approved to assess nutritional status 
mainly among the elderly people aged >65 yrs. Therefore, our data from younger 
patients might not be as valid as those from the older ones resulting in an 
information bias. However, in the validation study we showed that MNA could be a 
valid instrument for younger individuals as well [113]. In addition, two other 
studies have used MNA to assess nutritional status in participants with 
approximately the same range of age as ours [60, 164]. In study VI, data on some 
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other important PD-related features have been missed such as pain and RBD, which 
might potentially affect HRQoL. Data validity could have been improved by using 
more objective methods like polysomnography for sleep disturbances, blood 
pressure measurement to detect orthostatic hypotension and a full 
neuropsychological assessment for cognitive impairments. Nonetheless, we had 
some resource, instrumental and time restrictions to perform all these measurements 
that could be addressed for future studies on determinants of HRQoL.     
• Confounders: Although an age- and sex-matched control group was recruited for 
comparisons of nutritional status with PD patients in study IV, the case group had 
significantly higher educational level considering as a proxy for better 
socioeconomic status that could have confounded nutritional comparisons. This 
confounding effect might have compensated the potential influence of PD on 
nutritional status compared to the normal condition. This might have probably 
stemmed from the source of control selection. While controls were recruited from 
educational hospitals with free services (patients’ relatives), the cases were selected 
from an outpatient private clinic, which might have resulted in inconsistency of 
socioeconomical status. Nevertheless, multivariate analysis showed no significant 
difference in the average MNA score between PD patients and the controls even 
after adjustment for the imbalance in educational level [55]. 
5.2.2. Strengths 
The strengths of our project are as follows: 
• Comprehensive database: In study V and study VI, a broad list of variables 
including demographics, comorbidity profile, motor and non-motor symptoms, 
fatigue, full UPDRS, nutritional status and HRQoL was evaluated, which has 
enabled us to consider numerous interactions, look for independent determinants 
and increase the reliability and validity of our findings. In study VI and in addition 
to the broad list of motor and non-motor features, comorbidity profile and 
nutritional status were also included in our analysis, whereas these two important 
determinants have been mostly ignored in previous studies on HRQoL in PD. 
• Large sample size and sampling method: A large number of inhabitants (n=19,500) 
were recruited in the community-based door-to-door study through a well-designed 
multistage sampling that covered the whole urban area of Tehran. Consequently, the 
high statistical power and reliable representativeness of the samples have increased 
the validity of our findings in study III. In other studies where data were collected 
from the Movement Disorder Clinic, the recruited number of PD patients was 
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between 110 and 157, which is considered approximately high compared to the 
other similar studies on each topic.     
• Matched control group: In study IV, an age- and sex-matched control group was 
used from the same community with similar socio-economic background to 
compare the prevalence of malnutrition with that of the PD group. To the best of 
our knowledge, our study is one of the few to recruit such a matched control group, 
which has led to a more valid interpretation on the magnitude of malnutrition in 
people with PD.        
• Sophisticated statistical methods: In study II, we used the new statistical concept of 
CUI introduced by Mitchell [126, 165] to improve the interpretation of screening 
performance considering not only the diagnostic indices but also the occurrence of 
that symptom [165]. This simple approach resulted in selection of the most valid 
items, which globally demonstrated the best performance to screen parkinsonism. In 
addition to the multivariate regression model, which is the most common method 
that has been used to find determinant factors of HRQoL in PD [76], we also 
applied SEM in study VI. With respect to statistical considerations, SEMs are 
stronger models due to the ability of complex linkage between different components 
through simultaneous regression equations, and taking into account inter-
relationships between predictor variables and observational errors from 
measurement of latent variables [166], here motor and non-motor components.   
• Fair comparison: In study II where we attempted to compare different screening 
instruments, a comprehensive questionnaire was made through merging all 
previously developed tools consisting of 25 unique symptoms. Therefore, we were 
able to implement discriminant performance of all questionnaires on the same 
original database as our own new 6-item instrument was developed from. To the 
best of our knowledge, it was the first time to perform such a fair comparison 
between several screening tools for parkinsonism. 
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6 CONCLUSIONS 
6.1 General conclusion  
Using our novel 6-item screening instrument with high diagnostic accuracy, we showed a 
medium-to-high prevalence rate for suspicious parkinsonism in Iranian population living in the 
urban area of Tehran, Iran. With respect to some general aspects of life in PD, almost a similar 
nutritional status was found in mild-to-moderate PD patients and age- and sex-matched 
controls from the same community. Nevertheless, approximately one third of the PD 
population were either malnourished or at risk of malnutrition. Duration of PD, severity of 
motor symptoms, depression, anxiety and fatigue associated with nutritional status in people 
with PD. Different aspects of HRQoL were affected by nutritional status in PD patients, 
especially the emotional well-being and mobility domains. Motor symptoms affecting ADL, 
depression, anxiety and female sex were found to be the strongest independent determinants of 
HRQoL in Iranian PD population. Clear heterogeneities were demonstrated in the structural 
model to explain the pattern of HRQoL consisting of the list of determinants, contribution of 
motor and non-motor components and the projection of different domains of HRQoL in PD 
patients with different phenotypes regarding onset-age, progression rate and dominant features.          
 
6.2 Specific conclusions 
• Study I: The Persian version of the short-form PDQ (PDQ-8) is a reliable and valid 
instrument to assess HRQoL in Iranian PD population. Although the reliability 
coefficient of the PDQ-8 was lower than that of the long-form version (PDQ-39), it 
is still a valid tool to assess different domains of HRQoL especially the mental, 
emotional and behavioral aspects. Single items of the PDQ-8 were not necessarily 
those with the highest internal consistency within the corresponding components of 
the original PDQ-39, nevertheless, they entirely showed acceptable psychometric 
properties with no need for the replacement of any item. 
• Study II: Using the concept of CUI to select the best items, we developed a valid 
and reliable new screening questionnaire for parkinsonism. This new 6-item 
instrument was shown to have superior diagnostic values compared to the 
previously developed questionnaires for screening of parkinsonian in community-
based surveys. This short questionnaire consists of six items that could be easily 
administered by healthcare professionals in different age groups for screening of 
parkinsonian patients with even early-stage of the disease.  
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• Study III: Our estimation for the prevalence rate of parkinsonism is closer to the 
reports from some European and Eastern Mediterranean countries, higher than 
prevalence rates from Eastern Asian and African populations and lower than 
Australia. In general, a prevalence rate of >200/100,000 for parkinsonism in the 
urban area of Tehran, Iran is considered as medium-to-high. This prevalence rate 
has been estimated for a huge metropolitan with potentially high risk of exposure to 
pollutants, and other risk factors of urbanization. 
• Study IV: Although similar nutritional status was found in mild-to-moderate PD 
patients and healthy controls, approximately one third of them were either at risk of 
malnutrition or malnourished. It seems that eating problems and nutritional 
insufficiencies are more prevalent during the advanced stages of PD and among 
hospitalized severe cases. 
• Study V: Several non-motor features such as depression, anxiety and fatigue were 
related to nutritional status in PD patients as well as indicators of disease severity 
and level of morbidity. Regardless of patients’ age, longer disease duration 
determined worse nutritional status. Different aspects of the HRQoL namely 
mobility, ADL, emotional well-being, social support, cognition, communication and 
bodily discomfort closely associated with patients’ nutritional score.  
• Study VI: In general, ADL, depression, anxiety, and female sex were found to be 
the strongest determinants of HRQoL in Iranian PD patients using multivariate 
analysis. A comprehensive structural model has been also conceptualized for better 
understanding of HRQoL in PD. This model clarified the role of global motor and 
non-motor components and their most important indicators to affect HRQoL in 
addition to the comorbidity burden as the main drivers. Clear heterogeneous 
patterns were observed in patients with different phenotypes, which need to be 
taken into account for future interventions to improve HRQoL in people with PD. 
Based on our findings, more attention should be paid on the emotional well-being 
and stigma domain of HRQoL in PD patients at the beginning of their diagnosis. PD 
patients with younger-onset, older-onset, slow-progression, rapid-progression, 
motor-dominant, and non-motor-dominant phenotype have noticeably different 
causal pathways and determinants for HRQoL.	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7 RELEVANCE AND IMPLICATIONS 
Our findings have the following direct and indirect clinical and/or research relevance, some of 
which have been already implied and the others have potential implication: 
• Study I: In routine clinical practice with limited time, PDQ-8 is a practical and 
informative instrument that could be administered both either the clinicians, 
caregivers or PD patients themselves. Trans-cultural validation of the PDQ provides 
a unique opportunity to use this instrument as an international scale to measure 
improvements and/or changes in HRQoL as an important healthcare outcome in 
multi-center studies on PD populations including international clinical trials. Other 
than the PDQs, we validated the Persian-translated version of three other scales in 
people with PD namely FSS, SCOPA-PS and MNA. So far, three different study 
groups have contacted us for permission to use these validated Persian-translated 
scales in their researches on Iranian PD patients.   
• Study II: Our new screening instrument is a useful tool to estimate the prevalence of 
cases suspicious of parkinsonism, which can be applied in future 
neuroepidemiologic studies especially in poor-resource settings. We already used 
this instrument in study III in order to screen individuals with parkinsonism and 
estimate its prevalence rate.   
• Study III: Our study was the first attempt to estimate the prevalence of suspicious 
parkinsonism in Iranian population. These findings are great sources for healthcare 
policymakers in having evidence-based knowledge about the burden of 
parkinsonism. It is worth noting that our estimation on the probable prevalence of 
parkinsonism and PD in Iran has been already used as valid data source for the 
section of neurodegenerative disorders of the “Global Burden of Disease (GBD) 
Study 2013” project, the report which has been recently published as the global map 
of all human diseases [167].    
• Study IV: Regarding the prevalence rate of nutritional insufficiency among PD 
patients with even mild-to-moderate severity, it is reasonable to recommend 
clinicians screening their patients in any stage for malnutrition through longitudinal 
monitoring. Appropriate brief assessment tools such as the MNA together with 
anthropometric measurements can be used for this purpose. Educating patients and 
their caregivers about nutritional issues and recommending necessary and evidence-
based dietary interventions can be considered in multidisciplinary work-up of PD 
patients to prevent and/or handle malnutrition. Findings from study IV on the 
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prevalence of malnutrition in PD patients was released as relevant scientific news in 
simple language to be used by the PD patients’ communities and their relatives as 
well as other audiences who might be interested in this topic. The news was 
published by the IOS Press on 11 September 2014 and is accessible through the 
cited electronic link [168].       
• Study V: Our study was the first investigation looking for a better understanding of 
nutritional status among Iranian PD patients. Assessment of nutritional status 
should be considered in routine clinical practice of PD patients looking for risk of 
malnutrition and its negative effects on daily quality of life especially among those 
with more severe motor and non-motor features. More specifically, PD patients 
with more severe depressive symptoms, severe anxiety, severe fatigue, more severe 
disability with higher Hoehn and Yahr stage who are under a higher weight-
adjusted levodopa dose are more likely to develop malnutrition and may benefit 
more from nutritional screening. Our findings raised further hypothesis whether the 
individuals with insufficient nutrient intake in the past were more likely to present a 
more severe course of PD, or if the presence of more severe PD symptoms can 
hinder the capability and/or willingness to engage in appropriate nutritious meal 
preparation and dietary behaviors.  
• Study VI: As one of the first studies so far, we have deeply investigated 
heterogeneity in the pattern of HRQoL and the complex interactions between 
several various determinants in PD patients with different phenotypes. Our findings 
showed outstanding heterogeneities in the pattern and determinants of HRQoL 
between different PD phenotypes. These factors should be considered during the 
assessments and developing personalized interventions to improve HRQOL in PD 
patients with different phenotypes or prominent features. In other words, each 
person with PD must be evaluated for his/her more dominant phenotypic features, 
and thereafter a personalized approach should be planned for further evidence-
based assessments and interventions according to the heterogenic findings for each 
phenotype, some of which have been presented by our project.    
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8 FUTURE DIRECTIONS 
Based on our findings, the following specific directions and/or recommendations are proposed 
for future research on this topic:  
1) To further investigate the performance of the screening instrument for discrimination 
between PD versus APs such as MSA, PSP, CBD drug-induced parkinsonism, vascular 
parkinsonism and ET, studies with larger sample size of different APs are 
recommended. 
2) The rather medium-to-high prevalence rate of parkinsonism in Tehran, Iran needs to be 
further investigated for underlying reasons. Moreover, national comparisons with rural 
areas and between different Iranian ethnic groups are helpful to enlighten the 
neuroepidemiologic picture of parkinsonism as well as contribution of genetic and 
environmental factors in the incidence of parkinsonian syndrome. 
3) Longitudinal studies with appropriate follow-up examinations of PD patients in 
different stages including severe cases with advanced symptoms are needed to provide 
a more complete and accurate picture of the nutritional status in PD. Afterwards, valid 
causal relationships can be inferred to find modifiable exposures for future 
interventions.  Clinical trials are warranted to investigate the effects of nutritional 
interventions on prognosis and HRQoL in PD patients. 
4) Future studies to design, implement and assess the effects of multi-domain personalized 
interventions for each PD patients according to his/her dominant phenotype are highly 
demanded. The intervention should be designed individually targeting multiple 
domains namely motor symptoms and complications, psychiatric features, sleep 
disorders, autonomic disturbances, other NMSs, nutritional status and comorbidity 
profile.      
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Appendix 1. List of all questions and the selected items (bold font with star-marked number) 
for the new screening instrument for parkinsonism used in study II  
 
NO. Questions 
Answer 
No Yes Do not know 
1 
Have you ever had episodes of unconsciousness-that is, not 
understanding, not hearing, not seeing what was happening around 
you, and later not remembering what had happened during the loss 
of consciousness? 
o o o 
2 Have you ever had uncontrolled movements of your legs or arms? o o o 
3 Have there been serious changes in the way you speak? o o o 
4 Has your face or part of your face ever been paralyzed for more than 24 hours? o o o 
5 Has there ever been drooling from your mouth for more than 24 hours? o o o 
6 Have you ever had weakness in your arms or legs for more than 24 hours? o o o 
7 
Have you ever had abnormal sensation as tingling, burning, or loss 
of feeling in your arms and legs for more than 24 hours or less time 
but more than once? 
o o o 
8* Have you ever noticed stiffness in your legs? o o o 
9* Have you ever had tremors of your head, arms, or legs that lasted more than 1 day? o o o 
10 Is your handwriting smaller than it once was? o o o 
11 Do you have trouble arising from a chair? o o o 
12 Is your voice softer than it once was? o o o 
13 Have you recently consulted a doctor about shoulder pain? o o o 
14* Do you have trouble buttoning buttons or dressing? o o o 
15 Do you shuffle your feet and/or take smaller steps when you walk? o o o 
16* Have you or others noted that you do not swing one arm when you walk? o o o 
17 Is your balance poor? o o o 
18* Do your feet seem to get stuck to the floor when walking or turning? o o o 
19 Have you or others noted that you stoop or have abnormal posture? o o o 
20 Has your ability to smell changed? o o o 
21 Do you have dreams that make you act by screaming or fighting in your sleep? o o o 
22 Do you have trouble concentrating or remembering?  o o o 
23* Have you become slower in your usual daily activities?  o o o 
24 Do people tell you that your face seems less expressive than it once did? o o o 
25 Have you been unable to walk properly? o o o 
